{"trial_id":{"0":1758,"1":1757,"2":1756,"3":1755,"4":1754,"5":1753,"6":1750,"7":1725,"8":1724,"9":1719,"10":1694,"11":1685,"12":1548,"13":1547,"14":1545,"15":1541,"16":1540,"17":1531,"18":1526,"19":1525,"20":1524,"21":1523,"22":1522,"23":1503,"24":1499,"25":1498,"26":1483,"27":1438,"28":1417,"29":1349,"30":1348,"31":1339,"32":1331,"33":1160,"34":1157,"35":1153,"36":1148,"37":1107,"38":1098,"39":1094,"40":1090,"41":1085,"42":1081,"43":1074,"44":1073,"45":1062,"46":1061,"47":1054,"48":1051,"49":1046,"50":1045,"51":1036,"52":1035,"53":1024,"54":1014,"55":1010,"56":1006,"57":999,"58":993,"59":982,"60":978,"61":969,"62":965,"63":964,"64":961,"65":954,"66":948,"67":941,"68":937,"69":933,"70":927,"71":924,"72":919,"73":915,"74":910,"75":909,"76":906,"77":900,"78":896,"79":891,"80":887,"81":883,"82":878,"83":870,"84":869,"85":867,"86":864,"87":860,"88":856,"89":855,"90":854,"91":852,"92":851,"93":850,"94":849,"95":848,"96":846,"97":845,"98":833,"99":830,"100":828,"101":824,"102":821,"103":820,"104":819,"105":816,"106":815,"107":814,"108":813,"109":812,"110":811,"111":810,"112":809,"113":808,"114":807,"115":806,"116":805,"117":796,"118":784,"119":756,"120":748,"121":739,"122":736,"123":732,"124":731,"125":730,"126":729,"127":727,"128":726,"129":724,"130":723,"131":722,"132":721,"133":717,"134":715,"135":700,"136":697,"137":687,"138":667,"139":663,"140":659,"141":655,"142":650,"143":646,"144":642,"145":641,"146":640,"147":636,"148":634,"149":632,"150":602,"151":601,"152":600,"153":599,"154":587,"155":585,"156":582,"157":554,"158":553,"159":549,"160":543,"161":533,"162":511,"163":501,"164":494,"165":486,"166":485,"167":483,"168":482,"169":474,"170":459,"171":454,"172":333,"173":332,"174":330,"175":323,"176":322,"177":321,"178":320,"179":318,"180":317,"181":316,"182":315,"183":313,"184":312,"185":310,"186":309,"187":308,"188":305,"189":304,"190":295,"191":290,"192":289,"193":287,"194":268,"195":267,"196":266,"197":265,"198":264,"199":263,"200":262,"201":261,"202":260,"203":259,"204":258,"205":257,"206":256,"207":255,"208":254,"209":253,"210":252,"211":251,"212":250,"213":248,"214":245,"215":242,"216":234,"217":210,"218":206,"219":180,"220":179,"221":176,"222":173,"223":172,"224":170,"225":47,"226":9,"227":8,"228":7,"229":6,"230":5,"231":4,"232":3,"233":2},"discovery_date":{"0":1664127866297,"1":1664127866294,"2":1664127866292,"3":1664127866289,"4":1664127866286,"5":1664127866277,"6":1664127865485,"7":1659822704694,"8":1659822704689,"9":1659822703979,"10":1659307063578,"11":1659306161838,"12":1659107011689,"13":1659107011687,"14":1659107011682,"15":1659107011671,"16":1659107011662,"17":1659106903048,"18":1659096383560,"19":1659096383556,"20":1659096383554,"21":1659096383552,"22":1659096383550,"23":1658613647933,"24":1658613647890,"25":1658613647870,"26":1658613646520,"27":1657730506229,"28":1657730506206,"29":1657691771626,"30":1657691771626,"31":1657691771616,"32":1657691771608,"33":1657617117548,"34":1657617117511,"35":1657617117509,"36":1657574545568,"37":1657551017193,"38":1657551017179,"39":1657551017173,"40":1657551017161,"41":1657551017157,"42":1657551017149,"43":1657551017099,"44":1657551017098,"45":1656666072729,"46":1656666072728,"47":1656666072701,"48":1656666072713,"49":1656666072707,"50":1656666072706,"51":1656666072688,"52":1656666072682,"53":1656074136866,"54":1656074136856,"55":1656074136851,"56":1656074136845,"57":1656074136835,"58":1656074136821,"59":1655737257456,"60":1655737257450,"61":1655737257431,"62":1655737257425,"63":1655737257426,"64":1655737257420,"65":1655737257408,"66":1655737257232,"67":1655146470855,"68":1655146470847,"69":1655146470841,"70":1655146470835,"71":1655146470830,"72":1655146470823,"73":1655146470819,"74":1655146470766,"75":1655146470766,"76":1655146470756,"77":1654801184573,"78":1654801184537,"79":1654801184511,"80":1654801184465,"81":1654801184437,"82":1654801184381,"83":1654801184212,"84":1654801184213,"85":1654801184190,"86":1654801183960,"87":1654036127837,"88":1654036126898,"89":1654036126894,"90":1654036126891,"91":1654036126887,"92":1654036126885,"93":1654036126881,"94":1654036126877,"95":1654036126874,"96":1654036126867,"97":1654036126083,"98":1652792755721,"99":1652792755714,"100":1652792755702,"101":1652792755678,"102":1652646068589,"103":1652646068586,"104":1652646068582,"105":1652646068571,"106":1652646067879,"107":1652646067876,"108":1652646067872,"109":1652646067869,"110":1652646067866,"111":1652646067863,"112":1652646067855,"113":1652646067851,"114":1652646067847,"115":1652646067843,"116":1652646066967,"117":1651070653394,"118":1651070653334,"119":1650910207659,"120":1650910206842,"121":1650910206813,"122":1650910206804,"123":1650817401899,"124":1650817401896,"125":1650817401893,"126":1650817401890,"127":1650817401878,"128":1650817401303,"129":1650817401299,"130":1650817401297,"131":1650817401293,"132":1650817401290,"133":1650817401283,"134":1650817401278,"135":1650801472324,"136":1650801472299,"137":1650801472242,"138":1650024774188,"139":1650024774178,"140":1650024774173,"141":1650024774166,"142":1650024774144,"143":1650024774129,"144":1650024774115,"145":1650024774115,"146":1650024774113,"147":1650024773644,"148":1650024773648,"149":1650024773646,"150":1650017556654,"151":1650017556651,"152":1650017556648,"153":1650017556645,"154":1649805767662,"155":1649805767657,"156":1649805766972,"157":1649607834540,"158":1649607834536,"159":1649607834528,"160":1649607834515,"161":1649607833912,"162":1649346442235,"163":1649346442221,"164":1649346441434,"165":1649193374466,"166":1649193374464,"167":1649193374461,"168":1649193374458,"169":1649193374422,"170":1649193374385,"171":1649193373762,"172":1648920616068,"173":1648920616067,"174":1648920616062,"175":1648920616047,"176":1648920616046,"177":1648920616045,"178":1648920616043,"179":1648920616037,"180":1648920616027,"181":1648920616025,"182":1648920616024,"183":1648920616022,"184":1648920616020,"185":1648920616008,"186":1648920616006,"187":1648920616004,"188":1648920615320,"189":1648920615315,"190":1648681069243,"191":1648681069221,"192":1648681069217,"193":1648681069206,"194":1648589308071,"195":1648589308064,"196":1648589308056,"197":1648589308044,"198":1648589308036,"199":1648589308028,"200":1648589308020,"201":1648589308014,"202":1648589308008,"203":1648589308001,"204":1648589307995,"205":1648589307990,"206":1648589307978,"207":1648589307972,"208":1648589307965,"209":1648589307957,"210":1648589307950,"211":1648589307944,"212":1648589307930,"213":1648589307478,"214":1648589307460,"215":1648589307434,"216":1648424677254,"217":1648056908068,"218":1648056908052,"219":1647798026695,"220":1647798026692,"221":1647798026686,"222":1647798026674,"223":1647798026671,"224":1647798025855,"225":1647104801941,"226":1646853978171,"227":1646853978166,"228":1646853978164,"229":1646853978161,"230":1646853978158,"231":1646853978156,"232":1646853978152,"233":1646853977110},"title":{"0":"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases","1":"EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis","2":"The Effect of Reflexology and Pelvic Floor Muscle Exercises (Kegel) on Urinary Incontinence in MS Patients","3":"Cognitive Markers in Prodromal MS","4":"The Effects of Action Observation Therapy (AOT) on Balance and Gait in Patients With Multiple Sclerosis.","5":"Vancomycin Study in Multiple Sclerosis (MS)","6":"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR...","7":"Common and Specific Information From Neuroimaging and Smartphone","8":"Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis","9":"A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone...","10":"A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from...","11":"FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS","12":"A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis","13":"Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial.","14":"A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.","15":"A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long...","16":"A Phase 2, double-blind, randomized, placebo-controlled study assessing efficacy and safety of SAR441344, a CD40L-antagonist monoclonal antibody, in participants with relapsing multiple sclerosis","17":"Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis","18":"GentleCath\u2122 Air for Men Intermittent Catheter With FeelClean\u2122 Technology","19":"RELAXaHEAD for Headache Patients (Phase II)","20":"Lower Extremities Closed Kinetic Chain Exercises for People With MS","21":"Memory Rehabilitation Strategies in Patients With Multiple Sclerosis","22":"Effect of Tai Chi on Balance, Mood, Cognition, and Quality of Life in Patients With Multiple Sclerosis","23":"A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular ...","24":"A Multi-center, Randomized, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Inducible Urticaria (CINDU) in Adolescents and Adults Inadequately Controlled With H1-antihi ...","25":"A Randomized, Multicenter STudy to Evaluate the Effect of Secukinumab 300 mg s.c. Administered During 52 Weeks to Patients Suffering From New-onset Moderate to Severe Plaque Psoriasis as Early Intervention Compared to Standard Treatment With Narrow-b ...","26":"An Open-label, Non-randomized, Biopsy-based Mechanistic Study on Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ianalumab in Patients With Sj\u00f6gren&#39;s Syndrome","27":"A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in M ...","28":"An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","29":"A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subje ...","30":"2 Years Prospective Study to Collect Real-life Data On the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non- ...","31":"A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy","32":"A Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Doses of CFZ533 in Patients With Moderately Active Proliferative Lupus Nephritis","33":"A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) &amp; Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Pat ...","34":"A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)","35":"A Phase I&#x2F;II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ&#x2F;11 Mutant Melanomas","36":"Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)]","37":"Phase II&#x2F;III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging for the Detection of PSMA Positive Tumors Using Histopathology as a Standard of Truth","38":"A Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Investigate Efficacy, Safety, and Tolerability of LTP001 in Participants With Pulmonary Arterial Hypertension","39":"A Phase Ib&#x2F;II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","40":"Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and&#x2F;or Refractory Multiple Myeloma","41":"A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands","42":"A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare\u00ae Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera\u00ae Treatment","43":"A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)","44":"A Phase I&#x2F;Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15&#x2F;sIL-15R\u03b1)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma","45":"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositi ...","46":"A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants.","47":"A Post Marketing Surveillance on Lutathera\u00ae (Lutetium (177Lu) Oxodotreotide, 177Lu-DOTA0-Tyr3-Octreotate) in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) in Korea","48":"A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis","49":"A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)","50":"A Phase Ib&#x2F;II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-optimally to First-line Venetoclax Plus Azacitidine Treatment and in Pa ...","51":"A Randomized, Double-blind, Placebo-controlled, Japan Local Phase II Clinical Study Comparing Eltrombopag Monotherapy Versus Placebo in Adult Lower-risk Myelodysplastic Syndromes (MDS) Patients With Platelet Transfusion Dependence","52":"A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma ...","53":"A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients \u2265 18 Years of Age With Severe Uncontrolled Asthma.","54":"A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)","55":"Randomized, Single-dose, Open-label, Two-part, Two-period, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric With an Adult Formulation of Branaplam and to Investigate the Adult Formulation in Fed and Fasted St ...","56":"A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea&#x2F;Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive ...","57":"A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis","58":"A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinas ...","59":"A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients","60":"A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythem ...","61":"International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours","62":"Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma","63":"A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis","64":"An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments","65":"A Phase I&#x2F;Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced&#x2F;Relapsed ccRCC and Other Malignancies With HIF2\u03b1 Stabilizing Mutations","66":"A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon \u03b21) in Patients With Relapsing Multiple Sclerosis [AIOLOS]","67":"A Descriptive Study of PIK3CA Mutations and Outcomes With Alpelisib in Patients With HR-positive and HER2-negative Advanced Breast Cancer (ABC)&#x2F; Metastatic Breast Cancer (MBC) in India","68":"Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged \u2265 12 Years and &lt; 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies","69":"An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments","70":"Brolucizumab Treatment Experience Study of Patients With Neovascular Age-related Macular Degeneration (nAMD) in UK Routine Clinical Practice (BESRA)","71":"Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for Neovascular Age-related Macular Degeneration (nAMD) in Portugal","72":"Regulatory Post-Marketing Surveillance (rPMS) Study for Brolucizumab(Beovu \u00ae Injection, Beovu \u00aePrefilled Syringe)","73":"Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population","74":"Impact of Melanoma Adjuvant Treatment With Tafinlar\u00ae + Mekinist\u00ae (Dabrafenib + Trametinib) on Patients Quality of Life (QoL) and Clinical Outcomes in Portuguese Real World Setting","75":"Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD)","76":"A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis","77":"An Open Label Cryptosporidium Controlled Human Infection Model (CHIM) to Assess the Efficacy and Safety of ABO809 in Healthy Participants","78":"A Randomized, Open-label, Phase I&#x2F;II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients","79":"A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and&#x2F;or Refractory Multiple Myeloma","80":"A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase","81":"Investigator- and Subject-blinded, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy Trial of CFZ533 in Pediatric and Young Adult Subjects With New Onset Type 1 Diabetes (T1DM)","82":"A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer","83":"A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa","84":"A Phase I&#x2F;II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies","85":"A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Systemic Pharmacokinetics of Icenticaftor in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants","86":"A Phase I&#x2F;Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors","87":"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTI...","88":"Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction","89":"COVID 19 on Disease Activity in Radiologically Isolated Syndrome Cohort","90":"RIS International Cohort","91":"MUSCLE - Nordic Walking in MUltiple SCLErosis","92":"Clinical Correlates of Psychiatric Comorbidities in Patients With Multiple Sclerosis","93":"Ketamine for Multiple Sclerosis Fatigue","94":"An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis","95":"Intravoxel Incoherent Motion(IVIM) Magnetic Resonance Imaging in Multiple Sclerosis","96":"The Effect of an Interactive Web-based Program in the Management of Multiple Sclerosis","97":"Prospective Randomized Endovascular Therapy in Multiple Sclerosis","98":"The Relationship of Neuropathic Pain With Incontinence, Disability and Life Quality in Multiple Sclerosis Patients","99":"Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy","100":"An Online Lifestyle Modification Course for People With Multiple Sclerosis","101":"Investigation of the Effects of Motor Imagery and Action Observation Training in Individuals With Multiple Sclerosis","102":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and...","103":"A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon \u03b2-1a i.m. once weekly ...","104":"A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...","105":"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis","106":"Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity (RVTOX)","107":"TIME\u2122 at Home Feasibility Study: Evaluation of a Virtually Delivered, Community-based, Task-oriented Exercise Program","108":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","109":"Novel Imaging Markers in SPMS","110":"Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?","111":"Exopulse Mollii Suit, Spasticity & Tissue Oxygenation","112":"Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body","113":"Multiple Sclerosis Intimacy and Sexuality Questionnaire","114":"Cognitive-motor Telerehabilitation in MS","115":"A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis","116":"In-phase Bilateral Exercises in People With Relapsing Remitting Multiple Sclerosis","117":"CSF Free Kappa Light Chain for The Diagnosis of Demyelinating Disorders","118":"Metformin Treatment in Progressive Multiple Sclerosis","119":"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer\u2019s Disease ...","120":"Effect of Computerized Cognitive Training in Persons With MS","121":"Remote Exercise Effects on Cognitive Processing Speed in Multiple Sclerosis: A Pilot Trial","122":"A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis","123":"A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with neuromyelitis...","124":"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)","125":"Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS)","126":"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio\u00ae) in participants with relapsing forms of multiple sclerosis","127":"A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Onc...","128":"Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis","129":"Kinesiotape on Balance in With Multiple Sclerosis","130":"Study of Empathy in MS","131":"A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia\u00ae)","132":"Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis","133":"Proprioceptive Neuromuscular Facilitation in Multiple Sclerosis","134":"A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA\u00ae Indicated for Multiple Sclerosis","135":"A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients \u226518 Years of Age","136":"Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced&#x2F;Recurrent Non-small Cell Lung Cancer)","137":"A One-Year, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","138":"A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria","139":"A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan","140":"A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension","141":"A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD)","142":"Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)","143":"A Randomized, Open-label, Multi-center, Phase II Study of Asciminib Versus Best Available Therapy in Chinese Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors","144":"A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration","145":"More locations","146":"Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer&#39;s Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory ...","147":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)","148":"","149":"An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)","150":"Functional Outcomes From Diets in Multiple Sclerosis","151":"Effects of Telerehabilitation-Based Motor Imagery Training on Pain in People With Multiple Sclerosis","152":"Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis","153":"L Test in Multiple Sclerosis","154":"TENS in Persons With MS","155":"Therapeutic Effects of Line Dancing in People With MS","156":"Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis","157":"Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)","158":"Phase III: UbliTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)","159":"A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in pat...","160":"An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis","161":"Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients","162":"A 96-Weeks, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg\/kg\/day versus Placebo in the T...","163":"Post-authorization safety study to check the potential association between the safety\nprofile of beta interferon 1a and the body mass index or pharmacodynamics during the\ntitration phase","164":"Exercise and Pregnancy in People With Multiple Sclerosis","165":"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...","166":"The effect of Tecfidera\u00ae (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.","167":"A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re...","168":"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis","169":"A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (...","170":"Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis","171":"Multiple Sclerosis and Overactive Bladder Treatment","172":"A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX\u00ae (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respira...","173":"A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446\/ Placebo and a Single Dos...","174":"Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAM...","175":"A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis","176":"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)","177":"Effect of MD1003 in spinal progressive multiple sclerosis: a pivotal randomized double blind placebo controlled study","178":"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lu...","179":"An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o...","180":"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis","181":"A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300...","182":"A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis","183":"Multicenter, open-label, 12 weeks,\r\nphaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a\r\n(Rebif\u00ae) administered In the morning may affEct the severity of Flu-like syndrom...","184":"Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study","185":"A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects...","186":"Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T","187":"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.","188":"A Study for Tysabri Participant Preference","189":"Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials","190":"Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA\u00ae (efalizumab) in the framework of...","191":"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning fro...","192":"A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis","193":"A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUT...","194":"Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn\u2019s disease","195":"Ensayo de fase III, multic\u00e9ntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...","196":"A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS)","197":"An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician\u2019s choi...","198":"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSIN...","199":"A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis.","200":"Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters.\nA cross-over, double-blinded, placebo-controlled study.","201":"A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN\nPATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSO...","202":"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS","203":"Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis","204":"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","205":"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...","206":"Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously ...","207":"A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)","208":"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe...","209":"A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis","210":"Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri\u00ae in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)","211":"AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS","212":"A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex\u00ae (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis","213":"Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study","214":"Gait Analysis in Multiple Sclerosis Patients","215":"Drug Repurposing for Improving the Therapeutic Outcome in Multiple Sclerosis Patients","216":"B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis","217":"An Assistive Powered Wheelchair: Stage 2 Trial","218":"Cellular microRNA Signatures in Multiple Sclerosis","219":"A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers","220":"Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients","221":"Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis","222":"Famciclovir in Multiple Sclerosis","223":"Kesimpta\u00ae (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study","224":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","225":"Neuromodulation in MS Using Translingual Stimulation","226":"Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype","227":"Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf","228":"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","229":"Exploring Cortical Remyelination in Children With Multiple Sclerosis","230":"A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis","231":"Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)","232":"Covid-19 Vaccine Immune Response in Multiple Sclerosis","233":"Function Magnetic Resonance Imaging to Assess Two Therapeutic Strategies in Multiple Sclerosis (NeuroRehEM)."},"summary":{"0":"<b>Conditions<\/b>: \u00a0  Autoimmune\u00a0Diseases; \u00a0 Inflammatory\u00a0Disease; \u00a0 Acquired\u00a0Bone\u00a0Marrow\u00a0Aplasia; \u00a0 Systemic\u00a0Lupus\u00a0Erythematosus; \u00a0 Multiple\u00a0Sclerosis; \u00a0 Gvhd; \u00a0 Rheumatoid\u00a0Arthritis; \u00a0 Autoimmune\u00a0Thyroiditis; \u00a0 Vitiligo; \u00a0 Alopecia; \u00a0 Atopic\u00a0Dermatitis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Blood\u00a0sample\u00a0taken\u00a0at\u00a0a\u00a0single\u00a0time\u00a0point<br \/><b>Sponsor<\/b>: \u00a0  Assistance\u00a0Publique\u00a0-\u00a0H\u00f4pitaux\u00a0de\u00a0Paris<br \/><b>Not yet recruiting<\/b>","1":"<b>Condition<\/b>: \u00a0  Cognitive\u00a0Change<br \/><b>Intervention<\/b>: \u00a0  Behavioral:\u00a0EMRESERVA<br \/><b>Sponsor<\/b>: \u00a0  Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla<br \/><b>Recruiting<\/b>","2":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Reflexology; \u00a0 Urinary\u00a0Incontinence<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Reflexology\u00a0and\u00a0kegel\u00a0exercises<br \/><b>Sponsor<\/b>: \u00a0  Ondokuz\u00a0May\u0131s\u00a0University<br \/><b>Recruiting<\/b>","3":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Device:\u00a0Active\u00a0tDCS<br \/><b>Sponsors<\/b>: \u00a0  NYU\u00a0Langone\u00a0Health; \u00a0 National\u00a0Multiple\u00a0Sclerosis\u00a0Society<br \/><b>Recruiting<\/b>","4":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Behavioral:\u00a0Action\u00a0Observation\u00a0Therapy<br \/><b>Sponsor<\/b>: \u00a0  Shiraz\u00a0University\u00a0of\u00a0Medical\u00a0Sciences<br \/><b>Not yet recruiting<\/b>","5":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0Vancomycin; \u00a0 Drug:\u00a0Placebo<br \/><b>Sponsors<\/b>: \u00a0  Icahn\u00a0School\u00a0of\u00a0Medicine\u00a0at\u00a0Mount\u00a0Sinai; \u00a0 Doris\u00a0Duke\u00a0Charitable\u00a0Foundation<br \/><b>Not yet recruiting<\/b>","6":"<p>EudraCT Number: 2019-003919-53<br \/>Sponsor Protocol Number: GN41791<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2020-12-17<br \/>Medical condition: Primary Progressive multiple sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003919-53\/IT\">IT<\/a> (Ongoing)<\/p>","7":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0eGait<br \/><b>Sponsors<\/b>: \u00a0  Nantes\u00a0University\u00a0Hospital; \u00a0 Rennes\u00a0University\u00a0Hospital<br \/><b>Not yet recruiting<\/b>","8":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Interventions<\/b>: \u00a0  Other: Autologous hematopoietic stem cell transplantation; \u00a0 Drug:\u00a0Cyclophosphamide\/ATG; \u00a0 Drug:\u00a0Cyclophosphamide\/Rituximab<br \/><b>Sponsor<\/b>: \u00a0  Scripps\u00a0Health<br \/><b>Recruiting<\/b>","9":"<p>EudraCT Number: 2006-001827-21<br \/>Sponsor Protocol Number: CoSim-01<br \/>Sponsor Name: Glostrup Hospital, Dep. of Neurology<br \/>Start Date: 2009-03-06<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-001827-21\/DK\">DK<\/a> (Prematurely Ended)<\/p>","10":"<p>EudraCT Number: 2011-001442-15<br \/>Sponsor Protocol Number: CFTY720D2324<br \/>Sponsor Name: Novartis Pharma Services AG<br \/>Start Date: 2011-08-26<br \/>Medical condition: relapsing remitting multiple sclerosis<br \/>Disease: <br \/>Version: 14.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/GR\">GR<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/AT\">AT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/FI\">FI<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/HU\">HU<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/SE\">SE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001442-15\/IT\">IT<\/a> (Prematurely Ended)<\/p>","11":"<p>EudraCT Number: 2013-001409-10<br \/>Sponsor Protocol Number: FATIMS1.0<br \/>Sponsor Name: Odense University Hospital<br \/>Start Date: 2013-08-08<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 14.1<br \/>SOC Term: 100000004852<br \/>Classification Code: 10039720<br \/>Term: Sclerosis multiple<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-001409-10\/DK\">DK<\/a> (Prematurely Ended)<\/p>","12":"<p>EudraCT Number: 2005-001567-55<br \/>Sponsor Protocol Number: DAC-1012<br \/>Sponsor Name: Protein Design Labs, Inc.<br \/>Start Date: 2006-06-23<br \/>Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ...<br \/>Disease: <br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001567-55\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001567-55\/AT\">AT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001567-55\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001567-55\/ES\">ES<\/a> (Completed)<\/p>","13":"<p>EudraCT Number: 2012-003418-15<br \/>Sponsor Protocol Number: SSP<br \/>Sponsor Name: Medizinische Universit\u00e4t Wien<br \/>Start Date: 2012-10-23<br \/>Medical condition: Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step ph...<br \/>Disease: <br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003418-15\/AT\">AT<\/a> (Prematurely Ended)<\/p>","14":"<p>EudraCT Number: 2004-002571-16<br \/>Sponsor Protocol Number: MBP8298-01 Amendment 04<br \/>Sponsor Name: BioMS Technology Corp<br \/>Start Date: 2007-06-29<br \/>Medical condition: Secondary progressive multiple sclerosis<br \/>Disease: <br \/>Version: 8.1<br \/>SOC Term: <br \/>Classification Code: 10063400<br \/>Term: Secondary progressive multiple sclerosis<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/SE\">SE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/FI\">FI<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/DK\">DK<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/EE\">EE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/NL\">NL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/LT\">LT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002571-16\/LV\">LV<\/a> (Completed)<\/p>","15":"<p>EudraCT Number: 2022-000049-34<br \/>Sponsor Protocol Number: ACT16753<br \/>Sponsor Name: Sanofi-aventis recherche & d\u00e9veloppement<br \/>Start Date: 2022-07-21<br \/>Medical condition: Multiple sclerosis<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2022-000049-34\/ES\">ES<\/a> (Ongoing)<\/p>","16":"<p>EudraCT Number: 2020-004785-19<br \/>Sponsor Protocol Number: ACT16877<br \/>Sponsor Name: Sanofi-Aventis Recherche et D\u00e9veloppement<br \/>Start Date: 2021-06-01<br \/>Medical condition: Multiple sclerosis<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004785-19\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004785-19\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004785-19\/BG\">BG<\/a> (Ongoing)<\/p>","17":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other: Circuit training followed by telerehabilitation; \u00a0 Other:\u00a0Usual\u00a0care<br \/><b>Sponsor<\/b>: \u00a0  Brno\u00a0University\u00a0Hospital<br \/><b>Not yet recruiting<\/b>","18":"<b>Conditions<\/b>: \u00a0  Bladder\u00a0Outlet\u00a0Obstruction; \u00a0 Multiple\u00a0Sclerosis; \u00a0 Cauda\u00a0Equina\u00a0Syndrome; \u00a0 Enlarged Prostate With Lower Urinary Tract Symptoms; \u00a0 Parkinson\u00a0Disease; \u00a0 Lower\u00a0Urinary\u00a0Tract\u00a0Symptoms; \u00a0 Detrusor\u00a0Underactivity; \u00a0 Spinal\u00a0Cord\u00a0Injuries<br \/><b>Intervention<\/b>: \u00a0  Device:\u00a0Intermittent\u00a0self-catheterisation<br \/><b>Sponsor<\/b>: \u00a0  ConvaTec\u00a0Inc.<br \/><b>Not yet recruiting<\/b>","19":"<b>Conditions<\/b>: \u00a0  Migraine; \u00a0 Headache; \u00a0 Multiple\u00a0Sclerosis; \u00a0 Insomnia<br \/><b>Interventions<\/b>: \u00a0  Behavioral: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR); \u00a0 Behavioral:\u00a0Monitored\u00a0Usual\u00a0Care\u00a0(MUC)<br \/><b>Sponsors<\/b>: \u00a0  NYU\u00a0Langone\u00a0Health; \u00a0 Center\u00a0for\u00a0Advancing\u00a0Point\u00a0of\u00a0Care\u00a0Technologies; \u00a0 National\u00a0Heart,\u00a0Lung,\u00a0and\u00a0Blood\u00a0Institute\u00a0(NHLBI)<br \/><b>Recruiting<\/b>","20":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Combination Product: Telko plus conventional physical therapy (CPT)<br \/><b>Sponsor<\/b>: \u00a0  Anas\u00a0Radi\u00a0Hassan\u00a0Alashram<br \/><b>Recruiting<\/b>","21":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral:\u00a0Cognitive\u00a0Rehabilitation; \u00a0 Behavioral:\u00a0Combined\u00a0Rehabilitation; \u00a0 Behavioral:\u00a0Motor\u00a0Rehabilitation<br \/><b>Sponsor<\/b>: \u00a0  I.R.C.C.S.\u00a0Fondazione\u00a0Santa\u00a0Lucia<br \/><b>Completed<\/b>","22":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other: \"Tai-chi\" - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes<br \/><b>Sponsor<\/b>: \u00a0  Comenius\u00a0University<br \/><b>Completed<\/b>","23":"","24":"","25":"","26":"","27":"","28":"","29":"","30":"","31":"","32":"","33":"","34":"","35":"","36":"","37":"","38":"","39":"","40":"","41":"","42":"","43":"","44":"","45":"","46":"","47":"","48":"","49":"","50":"","51":"","52":"","53":"","54":"","55":"","56":"","57":"","58":"","59":"","60":"","61":"","62":"","63":"","64":"","65":"","66":"","67":"","68":"","69":"","70":"","71":"","72":"","73":"","74":"","75":"","76":"","77":"","78":"","79":"","80":"","81":"","82":"","83":"","84":"","85":"","86":"","87":"<p>EudraCT Number: 2020-004128-41<br \/>Sponsor Protocol Number: WN42086<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2021-08-24<br \/>Medical condition: Relapsing-Remitting Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Children, Adolescents, Under 18<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004128-41\/BE\">BE<\/a> (Ongoing)<\/p>","88":"<b>Conditions<\/b>: \u00a0  Neurogenic\u00a0Dysfunction\u00a0of\u00a0the\u00a0Urinary\u00a0Bladder; \u00a0 Multiple\u00a0Sclerosis; \u00a0 Sacral\u00a0Neuromodulation; \u00a0 Bowel\u00a0Dysfunction; \u00a0 Sexual\u00a0Dysfunction; \u00a0 Quality\u00a0of\u00a0Life<br \/><b>Interventions<\/b>: \u00a0  Device:\u00a0Turning\u00a0ON\u00a0the\u00a0neuromodulator; \u00a0 Device:\u00a0Turning\u00a0OFF\u00a0the\u00a0neuromodulator<br \/><b>Sponsor<\/b>: \u00a0  Odense\u00a0University\u00a0Hospital<br \/><b>Recruiting<\/b>","89":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 COVID-19<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0NO\u00a0intervention<br \/><b>Sponsor<\/b>: \u00a0  Centre\u00a0Hospitalier\u00a0Universitaire\u00a0de\u00a0Nice<br \/><b>Not yet recruiting<\/b>","90":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Radiologically\u00a0Isolated\u00a0Syndrome<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0No\u00a0intervention<br \/><b>Sponsor<\/b>: \u00a0  Centre\u00a0Hospitalier\u00a0Universitaire\u00a0de\u00a0Nice<br \/><b>Recruiting<\/b>","91":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Chronic\u00a0Progressive; \u00a0 Multiple\u00a0Sclerosis; \u00a0 Multiple\u00a0Sclerosis,\u00a0Primary\u00a0Progressive; \u00a0 Multiple\u00a0Sclerosis,\u00a0Secondary\u00a0Progressive<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Nordic\u00a0Walking\u00a0(NWG); \u00a0 Other:\u00a0Free\u00a0Walking\u00a0(FWG); \u00a0 Other:\u00a0Health\u00a0Education\u00a0(HEG)<br \/><b>Sponsors<\/b>: \u00a0  Leonardo\u00a0A.\u00a0Peyr\u00e9-Tartaruga; \u00a0 Aline\u00a0Nogueira\u00a0Haas; \u00a0 Fl\u00e1via\u00a0Gomes\u00a0Martinez<br \/><b>Not yet recruiting<\/b>","92":"<b>Condition<\/b>: \u00a0  Patients\u00a0With\u00a0Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0hospital\u00a0anxiety\u00a0and\u00a0depression\u00a0scale<br \/><b>Sponsor<\/b>: \u00a0  Sohag\u00a0University<br \/><b>Not yet recruiting<\/b>","93":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis\u00a0Fatigue<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0Ketamine; \u00a0 Drug:\u00a0Midazolam<br \/><b>Sponsors<\/b>: \u00a0  Johns\u00a0Hopkins\u00a0University; \u00a0 United\u00a0States\u00a0Department\u00a0of\u00a0Defense<br \/><b>Not yet recruiting<\/b>","94":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Biological:\u00a0BCD-132; \u00a0 Drug:\u00a0Teriflunomide<br \/><b>Sponsor<\/b>: \u00a0  Biocad<br \/><b>Recruiting<\/b>","95":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other: Diffusion-weighted magnetic resonance imaging<br \/><b>Sponsor<\/b>: \u00a0  Chinese\u00a0University\u00a0of\u00a0Hong\u00a0Kong<br \/><b>Not yet recruiting<\/b>","96":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Behavioral:\u00a0Y\u00f6netebilirim<br \/><b>Sponsor<\/b>: \u00a0  Selcuk\u00a0University<br \/><b>Not yet recruiting<\/b>","97":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Venous\u00a0Angioplasty; \u00a0 Other:\u00a0Sham\u00a0Angioplasty<br \/><b>Sponsors<\/b>: \u00a0  University\u00a0at\u00a0Buffalo; \u00a0 Volcano\u00a0Corporation<br \/><b>Completed<\/b>","98":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Disabilities\u00a0Multiple; \u00a0 Quality\u00a0of\u00a0Life; \u00a0 Incontinence,\u00a0Urinary; \u00a0 Incontinence\u00a0Bowel; \u00a0 Neuropathic\u00a0Pain<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Neuropathic\u00a0Pain<br \/><b>Sponsor<\/b>: \u00a0  Istanbul\u00a0University-Cerrahpasa<br \/><b>Recruiting<\/b>","99":"<b>Condition<\/b>: \u00a0  Active\u00a0Secondary\u00a0Progressive\u00a0Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0siponimod<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Not yet recruiting<\/b>","100":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral:\u00a0Lifestyle\u00a0modification; \u00a0 Behavioral:\u00a0Standard-care<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0of\u00a0Melbourne<br \/><b>Not yet recruiting<\/b>","101":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Motor\u00a0Imagery\u00a0training; \u00a0 Other:\u00a0Action\u00a0Observation\u00a0training; \u00a0 Other:\u00a0standard\u00a0rehabilitation<br \/><b>Sponsor<\/b>: \u00a0  Hacettepe\u00a0University<br \/><b>Not yet recruiting<\/b>","102":"<p>EudraCT Number: 2015-005431-41<br \/>Sponsor Protocol Number: BN40900(SA-309JG)<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd.<br \/>Start Date: 2017-10-16<br \/>Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 100000004852<br \/>Classification Code: 10029322<br \/>Term: Neuromyelitis optica<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005431-41\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005431-41\/HR\">HR<\/a> (Completed)<\/p>","103":"<p>EudraCT Number: 2011-005677-23<br \/>Sponsor Protocol Number: CFTY720D2311<br \/>Sponsor Name: Novartis Farma<br \/>Start Date: 2013-04-02<br \/>Medical condition: Relapsing multiple sclerosis<br \/>Disease: <br \/>Version: 15.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Children, Adolescents, Under 18<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/DE\">DE<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/RO\">RO<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/EE\">EE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005677-23\/HR\">HR<\/a> (Completed)<\/p>","104":"<p>EudraCT Number: 2012-003056-36<br \/>Sponsor Protocol Number: CBAF312A2304<br \/>Sponsor Name: Novartis Pharma Services AG<br \/>Start Date: 2012-10-31<br \/>Medical condition: Secondary progressive multiple sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063400<br \/>Term: Secondary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/IE\">IE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/SK\">SK<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-003056-36\/FR\">FR<\/a> (Ongoing)<\/p>","105":"<p>EudraCT Number: 2021-005746-15<br \/>Sponsor Protocol Number: MN43964<br \/>Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en Espa\u00f1a y que act\u00faa como representante F. Hoffmann-La Roche Ltd<br \/>Start Date: 2022-05-09<br \/>Medical condition: Primary Progressive Multiple Sclerosis (PPMS)\nRelapsing Multiple Sclerosis (RMS)<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-005746-15\/ES\">ES<\/a> (Ongoing)<\/p>","106":"<b>Condition<\/b>: \u00a0  Central\u00a0Neurogical\u00a0Impairment<br \/><b>Intervention<\/b>: \u00a0  Device:\u00a0DEEPSEN\u00a0virtual\u00a0reality\u00a0mask<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0Hospital,\u00a0Clermont-Ferrand<br \/><b>Recruiting<\/b>","107":"<b>Conditions<\/b>: \u00a0  Mobility\u00a0Limitation; \u00a0 Balance\u00a0Impairment<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0TIME\u2122\u00a0at\u00a0Home<br \/><b>Sponsors<\/b>: \u00a0  University\u00a0of\u00a0Toronto; \u00a0 March\u00a0of\u00a0Dimes,\u00a0Canada<br \/><b>Recruiting<\/b>","108":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis\u00a0(MS); \u00a0 Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting; \u00a0 Multiple\u00a0Sclerosis,\u00a0Primary\u00a0Progressive; \u00a0 Multiple\u00a0Sclerosis,\u00a0Chronic\u00a0Progressive; \u00a0 Multiple\u00a0Sclerosis\u00a0Relapse; \u00a0 Multiple\u00a0Sclerosis\u00a0Brain\u00a0Lesion; \u00a0 Multiple\u00a0Sclerosis\u00a0Benign<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0Clemastine\u00a0Fumarate; \u00a0 Drug:\u00a0Placebo<br \/><b>Sponsors<\/b>: \u00a0  University\u00a0of\u00a0California,\u00a0San\u00a0Francisco; \u00a0 United\u00a0States\u00a0Department\u00a0of\u00a0Defense<br \/><b>Not yet recruiting<\/b>","109":"<b>Conditions<\/b>: \u00a0  Secondary\u00a0Progressive\u00a0Multiple\u00a0Sclerosis; \u00a0 Multiple\u00a0Sclerosis,\u00a0Secondary\u00a0Progressive; \u00a0 Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0Ferumoxytol\u00a0infusion; \u00a0 Drug:\u00a0Gadoteridol; \u00a0 Diagnostic\u00a0Test:\u00a0MRI\u00a0Brain\u00a0and\u00a0Cervical\u00a0Spine<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0of\u00a0Utah<br \/><b>Recruiting<\/b>","110":"<b>Conditions<\/b>: \u00a0  Hypogammaglobulinemia; \u00a0 Multiple\u00a0Sclerosis; \u00a0 Fatigue<br \/><b>Intervention<\/b>: \u00a0  Diagnostic\u00a0Test:\u00a0Laboratory\u00a0test<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0Hospital\u00a0Inselspital,\u00a0Berne<br \/><b>Active, not recruiting<\/b>","111":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Device:\u00a0Exopulse\u00a0Mollii\u00a0Suit; \u00a0 Device:\u00a0Exopulse\u00a0Mollii\u00a0suit\u00a0(sham)<br \/><b>Sponsor<\/b>: \u00a0  Institut De La Colonne Vertebrale Et Des Neurosciences<br \/><b>Recruiting<\/b>","112":"<b>Conditions<\/b>: \u00a0  Parkinson\u00a0Disease; \u00a0 Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral: High Intensity Interval Training (HIIT); \u00a0 Behavioral:\u00a0Continuous\u00a0Aerobic\u00a0Training\u00a0(CAT); \u00a0 Behavioral:\u00a0Movement\u00a0Advice<br \/><b>Sponsors<\/b>: \u00a0  Amsterdam\u00a0UMC,\u00a0location\u00a0VUmc; \u00a0 Netherlands\u00a0Brain\u00a0Foundation<br \/><b>Recruiting<\/b>","113":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Sexual\u00a0Dysfunction; \u00a0 Questionnaires<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0descriptive\u00a0study<br \/><b>Sponsor<\/b>: \u00a0  Bozok\u00a0University<br \/><b>Completed<\/b>","114":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral:\u00a0Cognitive\u00a0training; \u00a0 Behavioral:\u00a0Motor\u00a0training<br \/><b>Sponsors<\/b>: \u00a0  Universitair\u00a0Ziekenhuis\u00a0Brussel; \u00a0 National\u00a0MS\u00a0Center\u00a0Melsbroek; \u00a0 Research\u00a0Foundation\u00a0Flanders<br \/><b>Not yet recruiting<\/b>","115":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-remitting<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0No\u00a0Intervention<br \/><b>Sponsor<\/b>: \u00a0  Eisai\u00a0Korea\u00a0Inc.<br \/><b>Completed<\/b>","116":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Behavioral: In-phase Bilateral Exercises of the upper limbs<br \/><b>Sponsors<\/b>: \u00a0  Cyprus\u00a0University\u00a0of\u00a0Technology; \u00a0 The Cyprus Foundation for Muscular Dystrophy Research<br \/><b>Not yet recruiting<\/b>","117":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Diagnostic\u00a0Test:\u00a0Kappa\u00a0Free\u00a0Light\u00a0Chain\u00a0(K-FLC)<br \/><b>Sponsor<\/b>: \u00a0  Aga\u00a0Khan\u00a0University<br \/><b>Completed<\/b>","118":"<b>Conditions<\/b>: \u00a0  Secondary\u00a0Progressive\u00a0Multiple\u00a0Sclerosis; \u00a0 Primary\u00a0Progressive\u00a0Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Drug: Metformin 500 Mg Oral Tablet, up to 4 tablets a day; \u00a0 Drug: Placebo oral tablet identical to metformin, up to 4 tablets a day<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0of\u00a0California,\u00a0Los\u00a0Angeles<br \/><b>Not yet recruiting<\/b>","119":"<p>EudraCT Number: 2017-002901-37<br \/>Sponsor Protocol Number: 251AD201<br \/>Sponsor Name: Biogen Idec Research Limited<br \/>Start Date: 2018-06-04<br \/>Medical condition: Mild cognitive impairment (MCI) due to Alzheimer\u2019s disease (AD) or mild AD<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 100000004852<br \/>Classification Code: 10001896<br \/>Term: Alzheimer's disease<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/SE\">SE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/FR\">FR<\/a> (Prematurely Ended)<\/p>","120":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Interventions<\/b>: \u00a0  Device:\u00a0BrainHQ\u00a0cognitive\u00a0training; \u00a0 Device:\u00a0BrainHQ\u00a0control\u00a0games<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0of\u00a0Nebraska<br \/><b>Not yet recruiting<\/b>","121":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral: Remotely Delivered and Supported Aerobic Walking Exercise Training; \u00a0 Behavioral: Remotely Delivered and Supported Stretching and Toning Exercise Training<br \/><b>Sponsor<\/b>: \u00a0  Kessler\u00a0Foundation<br \/><b>Not yet recruiting<\/b>","122":"<b>Condition<\/b>: \u00a0  Relapsing\u00a0Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0ofatumumab; \u00a0 Other:\u00a0glatiramer\u00a0acetate; \u00a0 Other:\u00a0interferon\u00a0\u03b21<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Not yet recruiting<\/b>","123":"<p>EudraCT Number: 2013-003752-21<br \/>Sponsor Protocol Number: BN40898(SA-307JG)<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd.<br \/>Start Date: 2014-05-19<br \/>Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 100000004852<br \/>Classification Code: 10029322<br \/>Term: Neuromyelitis optica<br \/>Level: LLT<br \/><br \/>Population Age: Adolescents, Under 18, Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/HU\">HU<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/ES\">ES<\/a> (Ongoing)<\/p>","124":"<p>EudraCT Number: 2021-000028-36<br \/>Sponsor Protocol Number: P3-IMU-838-RMS-01<br \/>Sponsor Name: Immunic AG<br \/>Start Date: 2022-01-18<br \/>Medical condition: Relapsing Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000028-36\/BG\">BG<\/a> (Ongoing)<\/p>","125":"<p>EudraCT Number: 2021-000307-20<br \/>Sponsor Protocol Number: COMB157GDE01<br \/>Sponsor Name: Novartis Pharma Vertriebs GmbH <br \/>Start Date: 2021-04-28<br \/>Medical condition: relapsing multiple sclerosis <br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000307-20\/DE\">DE<\/a> (Ongoing)<\/p>","126":"<p>EudraCT Number: 2020-000637-41<br \/>Sponsor Protocol Number: EFC16033<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2020-07-31<br \/>Medical condition: Relapsing Multiple Sclerosis <br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/FI\">FI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/IT\">IT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/RO\">RO<\/a> (Ongoing)<\/p>","127":"<p>EudraCT Number: 2011-005249-12<br \/>Sponsor Protocol Number: EFC11759<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2014-08-13<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 17.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Children, Adolescents, Under 18<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/EE\">EE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/GR\">GR<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/FR\">FR<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/LT\">LT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/3rd\">Outside EU\/EEA<\/a>, <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/IE\">IE<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/NL\">NL<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/SI\">SI<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/IT\">IT<\/a> (Not Authorised)<\/p>","128":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting; \u00a0 Adult\u00a0ALL; \u00a0 Vitamin\u00a0D3\u00a0Deficiency<br \/><b>Interventions<\/b>: \u00a0  Dietary\u00a0Supplement:\u00a025(OH)D3; \u00a0 Dietary\u00a0Supplement:\u00a0vitamin\u00a0D3<br \/><b>Sponsors<\/b>: \u00a0  Tehran\u00a0University\u00a0of\u00a0Medical\u00a0Sciences; \u00a0 Boston\u00a0University<br \/><b>Not yet recruiting<\/b>","129":"<b>Conditions<\/b>: \u00a0  Individuals\u00a0With\u00a0Multiple\u00a0Sclerosis; \u00a0 With\u00a0Ataxia\u00a0Symptoms; \u00a0 No\u00a0Secondary\u00a0Disease\u00a0Affecting\u00a0Balance<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Kinesiotape<br \/><b>Sponsor<\/b>: \u00a0  Firat\u00a0University<br \/><b>Recruiting<\/b>","130":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Interpersonal\u00a0Reactivity\u00a0Index<br \/><b>Sponsor<\/b>: \u00a0  Assistance\u00a0Publique\u00a0-\u00a0H\u00f4pitaux\u00a0de\u00a0Paris<br \/><b>Not yet recruiting<\/b>","131":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Intervention<\/b>: \u00a0  <br \/><b>Sponsor<\/b>: \u00a0  Bristol-Myers\u00a0Squibb<br \/><b>Recruiting<\/b>","132":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Internuclear\u00a0Ophthalmoplegia<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0Clemastine\u00a0Fumarate; \u00a0 Drug:\u00a0Placebo<br \/><b>Sponsor<\/b>: \u00a0  Amsterdam\u00a0UMC,\u00a0location\u00a0VUmc<br \/><b>Not yet recruiting<\/b>","133":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0PNF; \u00a0 Other:\u00a0Breathing\u00a0exercises<br \/><b>Sponsor<\/b>: \u00a0  Biruni\u00a0University<br \/><b>Not yet recruiting<\/b>","134":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Kesimpta<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Recruiting<\/b>","135":"","136":"","137":"","138":"","139":"","140":"","141":"","142":"","143":"","144":"","145":"","146":"","147":"","148":"","149":"","150":"<b>Conditions<\/b>: \u00a0  Relapsing\u00a0Remitting\u00a0Multiple\u00a0Sclerosis; \u00a0 Secondary\u00a0Progressive\u00a0Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral:\u00a0Glycemic\u00a0load; \u00a0 Behavioral:\u00a0Calorie\u00a0restriction; \u00a0 Behavioral:\u00a0Behavioral\u00a0support<br \/><b>Sponsors<\/b>: \u00a0  University\u00a0of\u00a0Alabama\u00a0at\u00a0Birmingham; \u00a0 Washington\u00a0University\u00a0School\u00a0of\u00a0Medicine; \u00a0 United\u00a0States\u00a0Department\u00a0of\u00a0Defense<br \/><b>Not yet recruiting<\/b>","151":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Pain<br \/><b>Intervention<\/b>: \u00a0  Behavioral: Telerehabilitation-based motor imagery training<br \/><b>Sponsors<\/b>: \u00a0  Dokuz\u00a0Eylul\u00a0University; \u00a0 Izmir\u00a0Katip\u00a0Celebi\u00a0University<br \/><b>Not yet recruiting<\/b>","152":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0cytof\u00a0analysis<br \/><b>Sponsor<\/b>: \u00a0  Rennes\u00a0University\u00a0Hospital<br \/><b>Recruiting<\/b>","153":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Behavioral:\u00a0L\u00a0test<br \/><b>Sponsor<\/b>: \u00a0  Firat\u00a0University<br \/><b>Recruiting<\/b>","154":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Device: Trancutaneous Electrical Nerve Stimulation; \u00a0 Other:\u00a0Strength\u00a0training; \u00a0 Device:\u00a0Sham\u00a0stimulation<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0Medical\u00a0Center\u00a0Groningen<br \/><b>Not yet recruiting<\/b>","155":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0line\u00a0dancing<br \/><b>Sponsors<\/b>: \u00a0  Gazi\u00a0University; \u00a0 Hacettepe\u00a0University; \u00a0 Fenerbahce\u00a0University<br \/><b>Completed<\/b>","156":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Immersive\u00a0Virtual\u00a0Reality\u00a0Intervention<br \/><b>Sponsors<\/b>: \u00a0  Glasgow\u00a0Caledonian\u00a0University; \u00a0 MS\u00a0Society,\u00a0UK; \u00a0 NHS\u00a0Lanarkshire<br \/><b>Not yet recruiting<\/b>","157":"<p>EudraCT Number: 2017-000638-75<br \/>Sponsor Protocol Number: TG1101-RMS301<br \/>Sponsor Name: TG Therapeutics<br \/>Start Date: 2017-12-05<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10029202<br \/>Term: Nervous system disorder<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000638-75\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000638-75\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000638-75\/ES\">ES<\/a> (Completed)<\/p>","158":"<p>EudraCT Number: 2017-000639-15<br \/>Sponsor Protocol Number: TG1101-RMS302<br \/>Sponsor Name: TG Therapeutics<br \/>Start Date: 2017-12-04<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10029202<br \/>Term: Nervous system disorder<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000639-15\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000639-15\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000639-15\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000639-15\/HR\">HR<\/a> (Completed)<\/p>","159":"<p>EudraCT Number: 2018-000001-23<br \/>Sponsor Protocol Number: DroSpas-1<br \/>Sponsor Name: Bionorica SE <br \/>Start Date: 2018-10-25<br \/>Medical condition: Symptomatic relief of spasticity in patients with multiple sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10029205<br \/>Term: Nervous system disorders<br \/>Level: SOC<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000001-23\/HU\">HU<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000001-23\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000001-23\/ES\">ES<\/a> (Completed)<\/p>","160":"<p>EudraCT Number: 2016-002937-31<br \/>Sponsor Protocol Number: MA30143<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2017-09-12<br \/>Medical condition: Relapsing remitting multiple sclerosis (RRMS)<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10039720<br \/>Term: Sclerosis multiple<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/NO\">NO<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/SI\">SI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/HR\">HR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/IT\">IT<\/a> (Ongoing)<\/p>","161":"<b>Conditions<\/b>: \u00a0  Fatigue; \u00a0 Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Ozanimod<br \/><b>Sponsors<\/b>: \u00a0  Brigham\u00a0and\u00a0Women's\u00a0Hospital; \u00a0 Bristol-Myers\u00a0Squibb<br \/><b>Not yet recruiting<\/b>","162":"<p>EudraCT Number: 2021-000639-30<br \/>Sponsor Protocol Number: AB20009<br \/>Sponsor Name: AB Science<br \/>Start Date: 2022-01-12<br \/>Medical condition: Patients with primary progressive or secondary progressive multiple sclerosis without relapse<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063400<br \/>Term: Secondary progressive multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000639-30\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000639-30\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000639-30\/GR\">GR<\/a> (Ongoing)<\/p>","163":"<p>EudraCT Number: 2006-000606-23<br \/>Sponsor Protocol Number: 26756<br \/>Sponsor Name: Merck, S.L.<br \/>Start Date: 2006-11-23<br \/>Medical condition: Not applicalbe<br \/>Disease: <br \/>Version: 14.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-000606-23\/ES\">ES<\/a> (Completed)<\/p>","164":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Pregnancy<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Moderate-intensity\u00a0cardiovascular\u00a0exercise<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0of\u00a0Alberta<br \/><b>Recruiting<\/b>","165":"<p>EudraCT Number: 2020-005929-89<br \/>Sponsor Protocol Number: CLOU064C12302<br \/>Sponsor Name: Novartis Pharma AG<br \/>Start Date: 2022-02-01<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005929-89\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005929-89\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005929-89\/SI\">SI<\/a> (Ongoing)<\/p>","166":"<p>EudraCT Number: 2015-001197-18<br \/>Sponsor Protocol Number: NOR-BGT-14-10665<br \/>Sponsor Name: Biogen Idec Norway<br \/>Start Date: 2015-05-20<br \/>Medical condition: multiple sclerosis<br \/>Disease: <br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-001197-18\/NO\">NO<\/a> (Completed)<\/p>","167":"<p>EudraCT Number: 2019-004822-15<br \/>Sponsor Protocol Number: GNC-401<br \/>Sponsor Name: GeNeuro Innovation SAS<br \/>Start Date: 2020-05-18<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004822-15\/SE\">SE<\/a> (Completed)<\/p>","168":"<p>EudraCT Number: 2021-000048-23<br \/>Sponsor Protocol Number: P2-IMU-838-PMS<br \/>Sponsor Name: Immunic AG<br \/>Start Date: 2021-10-28<br \/>Medical condition: Progressive forms of Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10053395<br \/>Term: Progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000048-23\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000048-23\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000048-23\/NL\">NL<\/a> (Ongoing)<\/p>","169":"<p>EudraCT Number: 2014-001579-30<br \/>Sponsor Protocol Number: TV5600-CNS-20006<br \/>Sponsor Name: Teva Pharmaceutical Industries Ltd.<br \/>Start Date: 2014-11-27<br \/>Medical condition: Primary Progressive Multiple Sclerosis<br \/>Disease: <br \/>Version: 19.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/IT\">IT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/NL\">NL<\/a> (Completed)<\/p>","170":"<p>EudraCT Number: 2018-004557-24<br \/>Sponsor Protocol Number: UKM17_0056<br \/>Sponsor Name: Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster c\/o Universit\u00e4tsklinikum M\u00fcnster, Gesch\u00e4ftsbereich Recht u. Drittmittel <br \/>Start Date: 2019-07-29<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004557-24\/DE\">DE<\/a> (Temporarily Halted)<\/p>","171":"<b>Condition<\/b>: \u00a0  Neurogenic\u00a0Bladder\u00a0Dysfunction<br \/><b>Interventions<\/b>: \u00a0  Device: Repetitive Transcranial Magnetic Stimulation; \u00a0 Device: Transcutaneous Posterior Tibial Nerve Stimulation<br \/><b>Sponsor<\/b>: \u00a0  Istanbul\u00a0Medipol\u00a0University\u00a0Hospital<br \/><b>Enrolling by invitation<\/b>","172":"<p>EudraCT Number: 2006-006299-39<br \/>Sponsor Protocol Number: 191622-082-01<br \/>Sponsor Name: Allergan<br \/>Start Date: 2008-04-23<br \/>Medical condition: Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy ...<br \/>Disease: <br \/>Version: 8.1<br \/>SOC Term: <br \/>Classification Code: 10046543<br \/>Term: Urinary incontinence<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-006299-39\/NL\">NL<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-006299-39\/FR\">FR<\/a> (Completed)<\/p>","173":"<p>EudraCT Number: 2010-018273-38<br \/>Sponsor Protocol Number: D1950C00011<br \/>Sponsor Name: AstraZeneca AB<br \/>Start Date: 2010-03-22<br \/>Medical condition: Alzheimer's Disease<br \/>Disease: <br \/>Version: 12.1<br \/>SOC Term: <br \/>Classification Code: 10001896<br \/>Term: Alzheimer's disease<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-018273-38\/FR\">FR<\/a> (Completed)<\/p>","174":"<p>EudraCT Number: 2009-011088-35<br \/>Sponsor Protocol Number: PACAMUS<br \/>Sponsor Name: Philipps-Universit\u00e4t Marburg<br \/>Start Date: 2010-03-24<br \/>Medical condition: Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP\/PACAP (vasoactive int...<br \/>Disease: <br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-011088-35\/DE\">DE<\/a> (Completed)<\/p>","175":"<p>EudraCT Number: 2011-001437-16<br \/>Sponsor Protocol Number: CFTY720D2319<br \/>Sponsor Name: Novartis Pharma Services AG<br \/>Start Date: 2012-09-19<br \/>Medical condition: multiple sclerosis<br \/>Disease: <br \/>Version: 15.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001437-16\/DE\">DE<\/a> (Completed)<\/p>","176":"<p>EudraCT Number: 2020-000645-14<br \/>Sponsor Protocol Number: EFC16035<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2020-10-13<br \/>Medical condition: Primary Progressive Multiple Sclerosis <br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/HR\">HR<\/a> (Ongoing)<\/p>","177":"<p>EudraCT Number: 2013-002113-35<br \/>Sponsor Protocol Number: MD1003CT2013-02MS-SPI<br \/>Sponsor Name: MEDDAY SAS<br \/>Start Date: Information not available in EudraCT<br \/>Medical condition: Progressive spinal multiple sclerosis<br \/>Disease: <br \/>Version: 18.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10053395<br \/>Term: Progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-002113-35\/FR\">FR<\/a> (Completed)<\/p>","178":"<p>EudraCT Number: 2015-000392-28<br \/>Sponsor Protocol Number: 1199.214<br \/>Sponsor Name: Boehringer Ingelheim bv<br \/>Start Date: 2015-11-02<br \/>Medical condition: Patients with Systemic Sclerosis and associated Interstitial Lung Disease<br \/>Disease: <br \/>Version: 19.1<br \/>SOC Term: 100000004859<br \/>Classification Code: 10012977<br \/>Term: Diffuse systemic sclerosis<br \/>Level: LLT<br \/>Version: 19.1<br \/>SOC Term: 100000004859<br \/>Classification Code: 10036814<br \/>Term: Progressive systemic sclerosis<br \/>Level: LLT<br \/>Version: 19.1<br \/>SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders<br \/>Classification Code: 10042954<br \/>Term: Systemic sclerosis pulmonary<br \/>Level: PT<br \/>Version: 19.1<br \/>SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders<br \/>Classification Code: 10025109<br \/>Term: Lung involvement in systemic sclerosis<br \/>Level: LLT<br \/>Version: 19.1<br \/>SOC Term: 100000004859<br \/>Classification Code: 10042953<br \/>Term: Systemic sclerosis<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/NL\">NL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/PT\">PT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/DK\">DK<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/GR\">GR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/FR\">FR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/IE\">IE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/FI\">FI<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/NO\">NO<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/SE\">SE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/AT\">AT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/HU\">HU<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/IT\">IT<\/a> (Completed)<\/p>","179":"<p>EudraCT Number: 2005-004061-41<br \/>Sponsor Protocol Number: 101-MS-321<br \/>Sponsor Name: BIOGEN IDEC LTD<br \/>Start Date: 2006-06-01<br \/>Medical condition: Multiple sclerosis (MS)<br \/>Disease: <br \/>Version: 14.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/GB\">GB<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/BE\">BE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/FI\">FI<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/IE\">IE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/AT\">AT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/SE\">SE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/HU\">HU<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/DK\">DK<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/CZ\">CZ<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/ES\">ES<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/IT\">IT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/GR\">GR<\/a> (Completed)<\/p>","180":"<p>EudraCT Number: 2020-000647-30<br \/>Sponsor Protocol Number: EFC16645<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2020-08-27<br \/>Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063400<br \/>Term: Secondary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/FI\">FI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/IT\">IT<\/a> (Ongoing)<\/p>","181":"<p>EudraCT Number: 2005-005985-35<br \/>Sponsor Protocol Number: 1206.15<br \/>Sponsor Name: Boehringer Ingelheim<br \/>Start Date: 2006-08-29<br \/>Medical condition: Relapsing forms of Multiple Sclerosis<br \/>Disease: <br \/>Version: 8.1<br \/>SOC Term: <br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-005985-35\/NL\">NL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-005985-35\/CZ\">CZ<\/a> (Prematurely Ended)<\/p>","182":"<p>EudraCT Number: 2016-004935-18<br \/>Sponsor Protocol Number: GNC-004<br \/>Sponsor Name: GeNeuro SA<br \/>Start Date: 2017-04-12<br \/>Medical condition: Multiple Sclerosis (MS)<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/HU\">HU<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/CZ\">CZ<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/ES\">ES<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/PL\">PL<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/BG\">BG<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/HR\">HR<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/IT\">IT<\/a> (Completed)<\/p>","183":"<p>EudraCT Number: 2013-004450-21<br \/>Sponsor Protocol Number: EMR200136-570<br \/>Sponsor Name: Merck Serono S.p.A.<br \/>Start Date: 2014-02-07<br \/>Medical condition: relapsing multiple sclerosis<br \/>Disease: <br \/>Version: 14.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004450-21\/IT\">IT<\/a> (Completed)<\/p>","184":"<p>EudraCT Number: 2013-002112-27<br \/>Sponsor Protocol Number: MD1003CT2013-01MS-ON<br \/>Sponsor Name: MEDDAY SAS<br \/>Start Date: Information not available in EudraCT<br \/>Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis<br \/>Disease: <br \/>Version: 18.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 18.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10030942<br \/>Term: Optic neuritis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-002112-27\/FR\">FR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-002112-27\/GB\">GB<\/a> (GB - no longer in EU\/EEA)<\/p>","185":"<p>EudraCT Number: 2004-000337-12<br \/>Sponsor Protocol Number: 24810<br \/>Sponsor Name: Serono International SA<br \/>Start Date: 2004-07-23<br \/>Medical condition: MS with 2 or more relapses within the last 2 years <br \/>Disease: <br \/>Version: 7.0<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: <br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-000337-12\/HU\">HU<\/a> (Completed)<\/p>","186":"<p>EudraCT Number: 2009-014857-34<br \/>Sponsor Protocol Number: FAU-001<br \/>Sponsor Name: Universit\u00e4tsklinikum Erlangen<br \/>Start Date: 2010-02-01<br \/>Medical condition: Patients with clinically definite MS or a clinically isolated episode of CNS involvement and disease dissemination in space, according to the McDonald\u2019s criteria<br \/>Disease: <br \/>Version: 12.0<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-014857-34\/DE\">DE<\/a> (Completed)<\/p>","187":"<p>EudraCT Number: 2004-000762-13<br \/>Sponsor Protocol Number: TV-5010\/202<br \/>Sponsor Name: TEVA ITALIA srl<br \/>Start Date: 2004-08-31<br \/>Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit.<br \/>Disease: <br \/>Version: 15.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-000762-13\/IT\">IT<\/a> (Completed)<\/p>","188":"<b>Condition<\/b>: \u00a0  Relapsing-Remitting\u00a0Multiple\u00a0Sclerosis\u00a0(RRMS)<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Natalizumab<br \/><b>Sponsor<\/b>: \u00a0  Biogen<br \/><b>Recruiting<\/b>","189":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  <br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Recruiting<\/b>","190":"<p>EudraCT Number: 2007-001377-28<br \/>Sponsor Protocol Number: 27577<br \/>Sponsor Name: Merck Serono International S.A.<br \/>Start Date: 2008-06-11<br \/>Medical condition: Adult patients with moderate to severe chronic plaque psoriasis \n-- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...<br \/>Disease: <br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10061664<br \/>Term: Autoimmune disorder<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10025139<br \/>Term: Lupus erythematosus systemic<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10047888<br \/>Term: Wegener's granulomatosis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10002817<br \/>Term: Antiphospholipid syndrome<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10040767<br \/>Term: Sjogren's syndrome<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10039073<br \/>Term: Rheumatoid arthritis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10045228<br \/>Term: Type I diabetes mellitus<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10011401<br \/>Term: Crohn's disease<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10009900<br \/>Term: Colitis ulcerative<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10003827<br \/>Term: Autoimmune hepatitis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10049046<br \/>Term: Autoimmune thyroiditis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10003822<br \/>Term: Autoimmune haemolytic anaemia NOS<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10034697<br \/>Term: Pernicious anemia<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10028417<br \/>Term: Myasthenia gravis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10018620<br \/>Term: Goodpasture's syndrome<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10018766<br \/>Term: Guillain Barre syndrome<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10043554<br \/>Term: Thrombocytopenia<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10037153<br \/>Term: Psoriasis<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/FR\">FR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/AT\">AT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/NL\">NL<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/PT\">PT<\/a> (Prematurely Ended)<\/p>","191":"<p>EudraCT Number: 2019-001341-40<br \/>Sponsor Protocol Number: COMB157G23101<br \/>Sponsor Name: Novartis Pharma AG<br \/>Start Date: 2020-05-07<br \/>Medical condition: Multiple sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/SI\">SI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/LV\">LV<\/a> (Ongoing)<\/p>","192":"<p>EudraCT Number: 2010-020338-25<br \/>Sponsor Protocol Number: WA25046<br \/>Sponsor Name: F.Hoffmann-La Roche<br \/>Start Date: 2010-11-02<br \/>Medical condition: Primary Progressive Multiple Sclerosis (PPMS)<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/FI\">FI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/BG\">BG<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/DK\">DK<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/PL\">PL<\/a> (Ongoing)<\/p>","193":"<p>EudraCT Number: 2020-005448-48<br \/>Sponsor Protocol Number: CN42097<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2022-03-15<br \/>Medical condition: Multiple Sclerosis (MS)<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005448-48\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005448-48\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005448-48\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005448-48\/IT\">IT<\/a> (Ongoing)<\/p>","194":"<p>EudraCT Number: 2006-004784-58<br \/>Sponsor Protocol Number: MRI-0143<br \/>Sponsor Name: University of Leuven<br \/>Start Date: 2007-06-22<br \/>Medical condition: Crohn's disease<br \/>Disease: <br \/>Version: 8.1<br \/>SOC Term: <br \/>Classification Code: 10011401<br \/>Term: Crohn's disease<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004784-58\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004784-58\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004784-58\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004784-58\/GB\">GB<\/a> (Prematurely Ended)<\/p>","195":"<p>EudraCT Number: 2007-005994-79<br \/>Sponsor Protocol Number: 3133K1-3000-WW<br \/>Sponsor Name: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development<br \/>Start Date: 2008-05-13<br \/>Medical condition: Enfermedad de Alzheimer\n\nAlzheimer Disease<br \/>Disease: <br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10012271<br \/>Term: Dementia Alzheimer's type<br \/>Level: PT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/ES\">ES<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/IE\">IE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/GB\">GB<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/FI\">FI<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/SE\">SE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/IT\">IT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/PT\">PT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/AT\">AT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/NL\">NL<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/DK\">DK<\/a> (Prematurely Ended)<\/p>","196":"<p>EudraCT Number: 2020-000579-19<br \/>Sponsor Protocol Number: MAGNET<br \/>Sponsor Name: Stichting TRICALS Foundation<br \/>Start Date: 2021-06-25<br \/>Medical condition: Amyotrophic Lateral Sclerosis<br \/>Disease: <br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000579-19\/NL\">NL<\/a> (Ongoing)<\/p>","197":"<p>EudraCT Number: 2020-004505-32<br \/>Sponsor Protocol Number: COMB157G3301<br \/>Sponsor Name: Novartis Pharma AG<br \/>Start Date: 2021-06-09<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004505-32\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004505-32\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004505-32\/IT\">IT<\/a> (Ongoing)<\/p>","198":"<p>EudraCT Number: 2020-001168-28<br \/>Sponsor Protocol Number: GN42272<br \/>Sponsor Name: F. Hoffman-La Roche<br \/>Start Date: 2021-03-01<br \/>Medical condition: Relapsing multiple sclerosis (RMS)<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001168-28\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001168-28\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001168-28\/IT\">IT<\/a> (Ongoing)<\/p>","199":"<p>EudraCT Number: 2005-001540-23<br \/>Sponsor Protocol Number: 309560<br \/>Sponsor Name: Schering Nordiska AB<br \/>Start Date: 2006-03-03<br \/>Medical condition: Early Secondary Progressive Multiple Sclerosis<br \/>Disease: <br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001540-23\/SE\">SE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001540-23\/DK\">DK<\/a> (Completed)<\/p>","200":"<p>EudraCT Number: 2012-005076-34<br \/>Sponsor Protocol Number: BEL-FMP-12-10325<br \/>Sponsor Name: Cliniques Universitaires Saint-Luc, Neurologie<br \/>Start Date: 2013-01-03<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005076-34\/BE\">BE<\/a> (Completed)<\/p>","201":"<p>EudraCT Number: 2017-004886-29<br \/>Sponsor Protocol Number: MN39158<br \/>Sponsor Name: Roche Farma SA (Soc unipersonal) que realiza el ensayo en Espa\u00f1a y que act\u00faa como representante F.Hoffmann-La Roche Ltd<br \/>Start Date: 2018-05-22<br \/>Medical condition: Multiple sclerosis (MS)<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10039720<br \/>Term: Sclerosis multiple<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/ES\">ES<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/IE\">IE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/FI\">FI<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/SI\">SI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/HR\">HR<\/a> (Ongoing)<\/p>","202":"<p>EudraCT Number: 2020-000893-69<br \/>Sponsor Protocol Number: BN42082<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2020-10-28<br \/>Medical condition: Relapsing Multiple Sclerosis (MS)<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10039720<br \/>Term: Sclerosis multiple<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/IT\">IT<\/a> (Ongoing)<\/p>","203":"<p>EudraCT Number: 2017-001362-25<br \/>Sponsor Protocol Number: RAM-MS<br \/>Sponsor Name: Helse Bergen HF, Haukeland University Hospital<br \/>Start Date: 2018-05-02<br \/>Medical condition: Relapsing remitting multiple sclerosis.<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001362-25\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001362-25\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001362-25\/NL\">NL<\/a> (Ongoing)<\/p>","204":"<p>EudraCT Number: 2015-002500-91<br \/>Sponsor Protocol Number: RPC01-3001<br \/>Sponsor Name: Celgene International II S\u00e0rl (CIS II)<br \/>Start Date: 2015-10-12<br \/>Medical condition: Relapsing Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/HR\">HR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/IT\">IT<\/a> (Ongoing)<\/p>","205":"<p>EudraCT Number: 2019-004980-36<br \/>Sponsor Protocol Number: MS200527-0082<br \/>Sponsor Name: Merck Healthcare KGaA<br \/>Start Date: 2020-09-21<br \/>Medical condition: Relapsing Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/NO\">NO<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/SI\">SI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/IT\">IT<\/a> (Ongoing)<\/p>","206":"<p>EudraCT Number: 2019-000069-19<br \/>Sponsor Protocol Number: MS700568_0026<br \/>Sponsor Name: Merck KGaA<br \/>Start Date: 2019-07-12<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10029205<br \/>Term: Nervous system disorders<br \/>Level: SOC<br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/SE\">SE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/PT\">PT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/EE\">EE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/BG\">BG<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/AT\">AT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/LT\">LT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/HR\">HR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/RO\">RO<\/a> (Completed)<\/p>","207":"<p>EudraCT Number: 2013-003884-71<br \/>Sponsor Protocol Number: LPS13649<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2015-02-05<br \/>Medical condition: Relapsing-remitting multiple sclerosis<br \/>Disease: <br \/>Version: 17.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/NL\">NL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/IT\">IT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/DK\">DK<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/HR\">HR<\/a> (Completed)<\/p>","208":"<p>EudraCT Number: 2020-002700-39<br \/>Sponsor Protocol Number: CBAF312D2301<br \/>Sponsor Name: Novartis Pharma AG<br \/>Start Date: 2021-09-10<br \/>Medical condition: Multiple Sclerosis in pediatric patients<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Children, Adolescents, Under 18<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/HR\">HR<\/a> (Ongoing)<\/p>","209":"<p>EudraCT Number: 2015-005160-41<br \/>Sponsor Protocol Number: ALK8700-A301<br \/>Sponsor Name: Biogen Idec Research Limited<br \/>Start Date: 2016-07-27<br \/>Medical condition: Relapsing Remitting Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/BG\">BG<\/a> (Completed)<\/p>","210":"<p>EudraCT Number: 2018-004751-20<br \/>Sponsor Protocol Number: PB006-03-01<br \/>Sponsor Name: Polpharma Biologics S.A.<br \/>Start Date: 2019-07-22<br \/>Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004751-20\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004751-20\/HR\">HR<\/a> (Completed)<\/p>","211":"<p>EudraCT Number: 2017-001313-93<br \/>Sponsor Protocol Number: MN39159<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2018-05-03<br \/>Medical condition: Progressive multiple sclerosis (PMS)<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10053395<br \/>Term: Progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/IE\">IE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/DE\">DE<\/a> (Ongoing)<\/p>","212":"<p>EudraCT Number: 2008-003098-42<br \/>Sponsor Protocol Number: 108MS303<br \/>Sponsor Name: Biogen Idec Ltd<br \/>Start Date: 2009-01-06<br \/>Medical condition: To evaluate the immunogenicity of Avonex\u00ae 30 mcg when administered SC to interferon-na\u00efve subjects with relapsing Multiple Sclerosis<br \/>Disease: <br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003098-42\/CZ\">CZ<\/a> (Completed)<\/p>","213":"<b>Conditions<\/b>: \u00a0  Systemic\u00a0Sclerosis; \u00a0 Multisystem\u00a0Disorder<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0MRI<br \/><b>Sponsors<\/b>: \u00a0  Tsinghua\u00a0University; \u00a0 Peking\u00a0Union\u00a0Medical\u00a0College\u00a0Hospital<br \/><b>Recruiting<\/b>","214":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 3D\u00a0Gait\u00a0Analysis; \u00a0 Vestibular\u00a0Rehabilitation<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Vestibular\u00a0exercises; \u00a0 Other:\u00a0Standard\u00a0neurorehabilitation\u00a0exercises<br \/><b>Sponsors<\/b>: \u00a0  Istanbul\u00a0K\u00fclt\u00fcr\u00a0University; \u00a0 Istanbul\u00a0University-Cerrahpasa<br \/><b>Not yet recruiting<\/b>","215":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Drug: Metformin 1000 mg (Cidophage\u00ae 1000 mg tablets, CID, Giza, Egypt) tablet; \u00a0 Drug:\u00a0Interferon\u00a0beta-1a<br \/><b>Sponsor<\/b>: \u00a0  German\u00a0University\u00a0in\u00a0Cairo<br \/><b>Not yet recruiting<\/b>","216":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Ocrelizumab<br \/><b>Sponsor<\/b>: \u00a0  VU\u00a0University\u00a0Medical\u00a0Center<br \/><b>Not yet recruiting<\/b>","217":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Stroke; \u00a0 Cystic\u00a0Fibrosis; \u00a0 Motor\u00a0Neurone\u00a0Disease; \u00a0 Craniocerebral\u00a0Trauma; \u00a0 Guillain-Barre\u00a0Syndrome<br \/><b>Intervention<\/b>: \u00a0  Device: Powered Wheelchair Obstacle Alerting System<br \/><b>Sponsors<\/b>: \u00a0  East Kent Hospitals University NHS Foundation Trust; \u00a0 University\u00a0of\u00a0Kent; \u00a0 Sussex\u00a0Community\u00a0NHS\u00a0Foundation\u00a0Trust; \u00a0 KU\u00a0Leuven; \u00a0 l'Institut sup\u00e9rieur de l'\u00e9lectronique et du num\u00e9rique (ISEN) Lille<br \/><b>Completed<\/b>","218":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Intervention<\/b>: \u00a0  Genetic:\u00a050\u00a0ml\u00a0blodd\u00a0sampling<br \/><b>Sponsors<\/b>: \u00a0  Institut\u00a0Pasteur; \u00a0 H\u00f6pital\u00a0La\u00a0Piti\u00e9-Salp\u00eatri\u00e8re<br \/><b>Not yet recruiting<\/b>","219":"<b>Condition<\/b>: \u00a0  Amyotrophic\u00a0Lateral\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0prosetin; \u00a0 Drug:\u00a0placebo<br \/><b>Sponsors<\/b>: \u00a0  ProJenX; \u00a0 Worldwide\u00a0Clinical\u00a0Trials<br \/><b>Recruiting<\/b>","220":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Autoimmune\u00a0Blistering\u00a0Disease; \u00a0 B-Cell\u00a0Deficiency<br \/><b>Intervention<\/b>: \u00a0  Biological:\u00a0COVID19\u00a0vaccine<br \/><b>Sponsors<\/b>: \u00a0  Yale\u00a0University; \u00a0 National Institute of Allergy and Infectious Diseases (NIAID); \u00a0 Robert\u00a0Leet\u00a0and\u00a0Clara\u00a0Guthrie\u00a0Patterson\u00a0Trust<br \/><b>Active, not recruiting<\/b>","221":"<b>Conditions<\/b>: \u00a0  Clinically\u00a0Isolated\u00a0Syndrome; \u00a0 Relapsing\u00a0Remitting\u00a0Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Device:\u00a0Eye-tracking<br \/><b>Sponsors<\/b>: \u00a0  McGill\u00a0University; \u00a0 Innodem\u00a0Neurosciences<br \/><b>Not yet recruiting<\/b>","222":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Famciclovir<br \/><b>Sponsor<\/b>: \u00a0  Queen\u00a0Mary\u00a0University\u00a0of\u00a0London<br \/><b>Recruiting<\/b>","223":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Ofatumumab<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Not yet recruiting<\/b>","224":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Biological:\u00a0Ocrelizumab; \u00a0 Drug:\u00a0Placebo\u00a0for\u00a0Ocrelizumab<br \/><b>Sponsors<\/b>: \u00a0  National Institute of Allergy and Infectious Diseases (NIAID); \u00a0 Autoimmunity\u00a0Centers\u00a0of\u00a0Excellence\u00a0(ACE)<br \/><b>Not yet recruiting<\/b>","225":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Combination Product: PT plus translingual stimulation device; \u00a0 Combination Product: PT plus translingual stimulation control device<br \/><b>Sponsors<\/b>: \u00a0  University\u00a0of\u00a0Saskatchewan; \u00a0 Memorial\u00a0University\u00a0of\u00a0Newfoundland<br \/><b>Enrolling by invitation<\/b>","226":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Sleep; \u00a0 Pain<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0Cannabidiol\u00a0(CBD); \u00a0 Drug:\u00a0Tetrahydrocannabinol\u00a0(THC); \u00a0 Drug:\u00a0Placebo\u00a0CBD; \u00a0 Drug:\u00a0Placebo\u00a0THC<br \/><b>Sponsors<\/b>: \u00a0  Tiffany\u00a0J.\u00a0Braley,\u00a0MD,\u00a0MS; \u00a0 National Center for Complementary and Integrative Health (NCCIH)<br \/><b>Not yet recruiting<\/b>","227":"<b>Condition<\/b>: \u00a0  Relapsing\u00a0Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Ofatumumab; \u00a0 Other:\u00a0Ocrelizumab<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Not yet recruiting<\/b>","228":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Natalizumab<br \/><b>Sponsor<\/b>: \u00a0  Biogen<br \/><b>Not yet recruiting<\/b>","229":"<b>Condition<\/b>: \u00a0  Children\u00a0With\u00a0Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0MRI\u00a0without\u00a0injection\u00a0of\u00a0contrast\u00a0product<br \/><b>Sponsor<\/b>: \u00a0  Assistance\u00a0Publique\u00a0-\u00a0H\u00f4pitaux\u00a0de\u00a0Paris<br \/><b>Not yet recruiting<\/b>","230":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Ocrelizumab<br \/><b>Sponsor<\/b>: \u00a0  Hoffmann-La\u00a0Roche<br \/><b>Not yet recruiting<\/b>","231":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  <br \/><b>Sponsors<\/b>: \u00a0  University\u00a0of\u00a0Michigan; \u00a0 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); \u00a0 Wayne\u00a0State\u00a0University; \u00a0 University\u00a0of\u00a0Washington<br \/><b>Not yet recruiting<\/b>","232":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Blood\u00a0Test\u00a01; \u00a0 Other:\u00a0Blood\u00a0Test\u00a02<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0Hospitals\u00a0of\u00a0North\u00a0Midlands\u00a0NHS\u00a0Trust<br \/><b>Recruiting<\/b>","233":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral:\u00a0N-back\u00a0Cognitive\u00a0Training; \u00a0 Behavioral: Virtual Reality Motor and Cognitive Training<br \/><b>Sponsor<\/b>: \u00a0  Universitat\u00a0Jaume\u00a0I<br \/><b>Recruiting<\/b>"},"link":{"0":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05544448?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05546424?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","2":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05541965?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","3":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05543915?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","4":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05543213?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","5":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05539729?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","6":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-003919-53","7":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05482906?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","8":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05482542?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","9":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-001827-21","10":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-001442-15","11":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-001409-10","12":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-001567-55","13":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-003418-15","14":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-002571-16","15":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2022-000049-34","16":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-004785-19","17":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05469568?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","18":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05470751?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","19":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05466682?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","20":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05460299?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","21":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05462678?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","22":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05474209?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","23":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03578367","24":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05024058","25":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03020199","26":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05124925","27":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05142696","28":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04720157","29":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04722666","30":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05155098","31":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04984876","32":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03610516","33":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04065841","34":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05030428","35":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05415072","36":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04838613","37":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04838626","38":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05135000","39":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04699188","40":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04318327","41":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct01351103","42":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04524442","43":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04903197","44":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04261439","45":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04251533","46":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05329623","47":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04946305","48":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03217422","49":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03940352","50":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05155709","51":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04797000","52":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04935359","53":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04410523","54":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04711135","55":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05330286","56":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03474965","57":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04074590","58":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04925479","59":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04641442","60":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03656562","61":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03691064","62":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05172596","63":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04886258","64":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04058756","65":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04895748","66":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05344469","67":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05022342","68":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04648930","69":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct02934568","70":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05112835","71":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04764656","72":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04985487","73":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04645589","74":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04547946","75":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04935411","76":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04064242","77":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05036668","78":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04097821","79":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04123418","80":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04971226","81":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04129528","82":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04294160","83":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct03827798","84":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct02900651","85":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04587622","86":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04237649","87":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-004128-41","88":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05380856?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","89":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05387395?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","90":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05388331?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","91":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05385731?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","92":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05382195?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","93":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05378100?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","94":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05385744?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","95":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05391906?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","96":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05393765?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","97":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05380362?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","98":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05374811?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","99":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05376579?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","100":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05374473?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","101":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05377476?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","102":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-005431-41","103":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-005677-23","104":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-003056-36","105":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-005746-15","106":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05364203?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","107":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05369741?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","108":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05359653?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","109":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05357833?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","110":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05357781?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","111":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05362006?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","112":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05357638?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","113":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05374031?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","114":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05355389?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","115":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05366036?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","116":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05367947?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","117":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05347277?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","118":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05349474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","119":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-002901-37","120":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05345288?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","121":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05344040?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","122":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05344469?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","123":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-003752-21","124":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-000028-36","125":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-000307-20","126":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000637-41","127":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-005249-12","128":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05340985?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","129":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05341895?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","130":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05332951?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","131":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05335031?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","132":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05338450?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","133":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05342025?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","134":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05334472?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","135":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04946318","136":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04575025","137":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04058067","138":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04812548","139":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05114746","140":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04926818","141":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04632056","142":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04781881","143":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04795427","144":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04679935","145":"https:\/\/www.novartis.com\/","146":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04795466","147":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04940065","148":"https:\/\/www.novartis.com\/","149":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04868968","150":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05327322?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","151":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05326711?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","152":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05326048?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","153":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05325359?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","154":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05321927?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","155":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05322915?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","156":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05320237?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","157":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-000638-75","158":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-000639-15","159":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-000001-23","160":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2016-002937-31","161":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05319093?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","162":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-000639-30","163":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-000606-23","164":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05313204?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","165":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-005929-89","166":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-001197-18","167":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-004822-15","168":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-000048-23","169":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2014-001579-30","170":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-004557-24","171":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05312138?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","172":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-006299-39","173":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2010-018273-38","174":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2009-011088-35","175":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-001437-16","176":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000645-14","177":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-002113-35","178":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-000392-28","179":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-004061-41","180":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000647-30","181":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-005985-35","182":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2016-004935-18","183":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-004450-21","184":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-002112-27","185":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-000337-12","186":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2009-014857-34","187":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-000762-13","188":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05304520?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","189":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05301907?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","190":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-001377-28","191":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-001341-40","192":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2010-020338-25","193":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-005448-48","194":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-004784-58","195":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-005994-79","196":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000579-19","197":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-004505-32","198":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001168-28","199":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-001540-23","200":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-005076-34","201":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-004886-29","202":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000893-69","203":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-001362-25","204":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-002500-91","205":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-004980-36","206":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-000069-19","207":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-003884-71","208":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-002700-39","209":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-005160-41","210":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-004751-20","211":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-001313-93","212":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2008-003098-42","213":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05297474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","214":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05299151?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","215":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05298670?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","216":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05296161?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","217":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05292690?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","218":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05290688?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","219":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05279755?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","220":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05286242?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","221":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05277740?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","222":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05283551?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","223":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05285904?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","224":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05285891?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","225":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05275049?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","226":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05269628?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","227":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05266469?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","228":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05265728?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","229":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05258396?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","230":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05269004?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","231":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05252195?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","232":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05269888?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","233":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05270239?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14"},"published_date":{"0":1663329600000,"1":1663588800000,"2":1663243200000,"3":1663329600000,"4":1663329600000,"5":1663156800000,"6":null,"7":1659355200000,"8":1659355200000,"9":null,"10":null,"11":null,"12":null,"13":null,"14":null,"15":null,"16":null,"17":1658404800000,"18":1658505600000,"19":1658332800000,"20":1657900800000,"21":1658160000000,"22":1658851200000,"23":null,"24":null,"25":null,"26":null,"27":null,"28":null,"29":null,"30":null,"31":null,"32":null,"33":null,"34":null,"35":null,"36":null,"37":null,"38":null,"39":null,"40":null,"41":null,"42":null,"43":null,"44":null,"45":null,"46":null,"47":null,"48":null,"49":null,"50":null,"51":null,"52":null,"53":null,"54":null,"55":null,"56":null,"57":null,"58":null,"59":null,"60":null,"61":null,"62":null,"63":null,"64":null,"65":null,"66":null,"67":null,"68":null,"69":null,"70":null,"71":null,"72":null,"73":null,"74":null,"75":null,"76":null,"77":null,"78":null,"79":null,"80":null,"81":null,"82":null,"83":null,"84":null,"85":null,"86":null,"87":null,"88":1652976000000,"89":1653408000000,"90":1653408000000,"91":1653321600000,"92":1652976000000,"93":1652889600000,"94":1653321600000,"95":1653580800000,"96":1653580800000,"97":1652889600000,"98":1652716800000,"99":1652803200000,"100":1652716800000,"101":1652803200000,"102":null,"103":null,"104":null,"105":null,"106":1651852800000,"107":1652284800000,"108":1651680000000,"109":1651593600000,"110":1651593600000,"111":1651766400000,"112":1651593600000,"113":1652457600000,"114":1651507200000,"115":1652112000000,"116":1652198400000,"117":1650988800000,"118":1651075200000,"119":null,"120":1650902400000,"121":1650902400000,"122":1650902400000,"123":null,"124":null,"125":null,"126":null,"127":null,"128":1650643200000,"129":1650643200000,"130":1650297600000,"131":1650384000000,"132":1650556800000,"133":1650643200000,"134":1650384000000,"135":null,"136":null,"137":null,"138":null,"139":null,"140":null,"141":null,"142":null,"143":null,"144":null,"145":null,"146":null,"147":null,"148":null,"149":null,"150":1649952000000,"151":1649865600000,"152":1649865600000,"153":1649865600000,"154":1649692800000,"155":1649779200000,"156":1649692800000,"157":null,"158":null,"159":null,"160":null,"161":1649433600000,"162":null,"163":null,"164":1649260800000,"165":null,"166":null,"167":null,"168":null,"169":null,"170":null,"171":1649174400000,"172":null,"173":null,"174":null,"175":null,"176":null,"177":null,"178":null,"179":null,"180":null,"181":null,"182":null,"183":null,"184":null,"185":null,"186":null,"187":null,"188":1648742400000,"189":1648742400000,"190":null,"191":null,"192":null,"193":null,"194":null,"195":null,"196":null,"197":null,"198":null,"199":null,"200":null,"201":null,"202":null,"203":null,"204":null,"205":null,"206":null,"207":null,"208":null,"209":null,"210":null,"211":null,"212":null,"213":1648483200000,"214":1648483200000,"215":1648483200000,"216":1648224000000,"217":1648051200000,"218":1647964800000,"219":1647360000000,"220":1647619200000,"221":1647273600000,"222":1647532800000,"223":1647619200000,"224":1647619200000,"225":1647018000000,"226":1646758800000,"227":1646413200000,"228":1646326800000,"229":1646067600000,"230":1646672400000,"231":1645635600000,"232":1646758800000,"233":1646758800000},"source":{"0":"","1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":"","9":"","10":"","11":"","12":16.0,"13":16.0,"14":16.0,"15":16.0,"16":16.0,"17":12.0,"18":12.0,"19":12.0,"20":12.0,"21":12.0,"22":12.0,"23":13.0,"24":13.0,"25":13.0,"26":13.0,"27":13.0,"28":13.0,"29":13.0,"30":13.0,"31":13.0,"32":13.0,"33":13.0,"34":13.0,"35":13.0,"36":13.0,"37":13.0,"38":13.0,"39":13.0,"40":13.0,"41":13.0,"42":13.0,"43":13.0,"44":13.0,"45":13.0,"46":13.0,"47":13.0,"48":13.0,"49":13.0,"50":13.0,"51":13.0,"52":13.0,"53":13.0,"54":13.0,"55":13.0,"56":13.0,"57":13.0,"58":13.0,"59":13.0,"60":13.0,"61":13.0,"62":13.0,"63":13.0,"64":13.0,"65":13.0,"66":13.0,"67":13.0,"68":13.0,"69":13.0,"70":13.0,"71":13.0,"72":13.0,"73":13.0,"74":13.0,"75":13.0,"76":13.0,"77":13.0,"78":13.0,"79":13.0,"80":13.0,"81":13.0,"82":13.0,"83":13.0,"84":13.0,"85":13.0,"86":13.0,"87":16.0,"88":12.0,"89":12.0,"90":12.0,"91":12.0,"92":12.0,"93":12.0,"94":12.0,"95":12.0,"96":12.0,"97":12.0,"98":12.0,"99":12.0,"100":12.0,"101":12.0,"102":16.0,"103":16.0,"104":16.0,"105":16.0,"106":12.0,"107":12.0,"108":12.0,"109":12.0,"110":12.0,"111":12.0,"112":12.0,"113":12.0,"114":12.0,"115":12.0,"116":12.0,"117":12.0,"118":12.0,"119":16.0,"120":12.0,"121":12.0,"122":12.0,"123":16.0,"124":16.0,"125":16.0,"126":16.0,"127":16.0,"128":12.0,"129":12.0,"130":12.0,"131":12.0,"132":12.0,"133":12.0,"134":12.0,"135":13.0,"136":13.0,"137":13.0,"138":13.0,"139":13.0,"140":13.0,"141":13.0,"142":13.0,"143":13.0,"144":13.0,"145":13.0,"146":13.0,"147":13.0,"148":13.0,"149":13.0,"150":12.0,"151":12.0,"152":12.0,"153":12.0,"154":12.0,"155":12.0,"156":12.0,"157":16.0,"158":16.0,"159":16.0,"160":16.0,"161":12.0,"162":16.0,"163":16.0,"164":12.0,"165":16.0,"166":16.0,"167":16.0,"168":16.0,"169":16.0,"170":16.0,"171":12.0,"172":16.0,"173":16.0,"174":16.0,"175":16.0,"176":16.0,"177":16.0,"178":16.0,"179":16.0,"180":16.0,"181":16.0,"182":16.0,"183":16.0,"184":16.0,"185":16.0,"186":16.0,"187":16.0,"188":12.0,"189":12.0,"190":16.0,"191":16.0,"192":16.0,"193":16.0,"194":16.0,"195":16.0,"196":16.0,"197":16.0,"198":16.0,"199":16.0,"200":16.0,"201":16.0,"202":16.0,"203":16.0,"204":16.0,"205":16.0,"206":16.0,"207":16.0,"208":16.0,"209":16.0,"210":16.0,"211":16.0,"212":16.0,"213":12.0,"214":12.0,"215":12.0,"216":12.0,"217":12.0,"218":12.0,"219":12.0,"220":12.0,"221":12.0,"222":12.0,"223":12.0,"224":12.0,"225":12.0,"226":12.0,"227":12.0,"228":12.0,"229":12.0,"230":12.0,"231":12.0,"232":12.0,"233":12.0},"relevant":{"0":"","1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":"","9":"","10":"","11":"","12":"","13":"","14":"","15":"","16":"","17":"","18":"","19":"","20":"","21":"","22":"","23":"","24":"","25":"","26":"","27":"","28":"","29":"","30":"","31":"","32":"","33":"","34":"","35":"","36":"","37":"","38":"","39":"","40":"","41":"","42":"","43":"","44":"","45":"","46":"","47":"","48":"","49":"","50":"","51":"","52":"","53":"","54":"","55":"","56":"","57":"","58":"","59":"","60":"","61":"","62":"","63":"","64":"","65":"","66":"","67":"","68":"","69":"","70":"","71":"","72":"","73":"","74":"","75":"","76":"","77":"","78":"","79":"","80":"","81":"","82":"","83":"","84":"","85":"","86":"","87":"","88":"","89":"","90":"","91":"","92":"","93":"","94":"","95":"","96":"","97":"","98":"","99":"","100":"","101":"","102":"","103":"","104":"","105":"","106":"","107":"","108":"","109":"","110":"","111":"","112":"","113":"","114":"","115":"","116":"","117":"","118":"","119":"","120":"","121":"","122":"","123":"","124":"","125":"","126":"","127":"","128":"","129":"","130":"","131":"","132":"","133":"","134":"","135":"","136":"","137":"","138":"","139":"","140":"","141":"","142":"","143":"","144":"","145":"","146":"","147":"","148":"","149":"","150":"","151":"","152":"","153":"","154":"","155":"","156":"","157":"","158":"","159":"","160":"","161":"","162":"","163":"","164":"","165":"","166":"","167":"","168":"","169":"","170":"","171":"","172":"","173":"","174":"","175":"","176":"","177":"","178":"","179":"","180":"","181":"","182":"","183":"","184":"","185":"","186":"","187":"","188":"","189":"","190":"","191":"","192":"","193":"","194":"","195":"","196":"","197":"","198":"","199":"","200":"","201":"","202":"","203":"","204":"","205":"","206":"","207":"","208":"","209":"","210":"","211":"","212":"","213":"","214":"","215":"","216":"","217":"","218":"","219":"","220":"","221":"","222":"","223":"","224":"","225":"","226":"","227":"","228":"","229":"","230":"","231":"","232":"","233":""},"Sources__source_id":{"0":"","1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":"","9":"","10":"","11":"","12":16.0,"13":16.0,"14":16.0,"15":16.0,"16":16.0,"17":12.0,"18":12.0,"19":12.0,"20":12.0,"21":12.0,"22":12.0,"23":13.0,"24":13.0,"25":13.0,"26":13.0,"27":13.0,"28":13.0,"29":13.0,"30":13.0,"31":13.0,"32":13.0,"33":13.0,"34":13.0,"35":13.0,"36":13.0,"37":13.0,"38":13.0,"39":13.0,"40":13.0,"41":13.0,"42":13.0,"43":13.0,"44":13.0,"45":13.0,"46":13.0,"47":13.0,"48":13.0,"49":13.0,"50":13.0,"51":13.0,"52":13.0,"53":13.0,"54":13.0,"55":13.0,"56":13.0,"57":13.0,"58":13.0,"59":13.0,"60":13.0,"61":13.0,"62":13.0,"63":13.0,"64":13.0,"65":13.0,"66":13.0,"67":13.0,"68":13.0,"69":13.0,"70":13.0,"71":13.0,"72":13.0,"73":13.0,"74":13.0,"75":13.0,"76":13.0,"77":13.0,"78":13.0,"79":13.0,"80":13.0,"81":13.0,"82":13.0,"83":13.0,"84":13.0,"85":13.0,"86":13.0,"87":16.0,"88":12.0,"89":12.0,"90":12.0,"91":12.0,"92":12.0,"93":12.0,"94":12.0,"95":12.0,"96":12.0,"97":12.0,"98":12.0,"99":12.0,"100":12.0,"101":12.0,"102":16.0,"103":16.0,"104":16.0,"105":16.0,"106":12.0,"107":12.0,"108":12.0,"109":12.0,"110":12.0,"111":12.0,"112":12.0,"113":12.0,"114":12.0,"115":12.0,"116":12.0,"117":12.0,"118":12.0,"119":16.0,"120":12.0,"121":12.0,"122":12.0,"123":16.0,"124":16.0,"125":16.0,"126":16.0,"127":16.0,"128":12.0,"129":12.0,"130":12.0,"131":12.0,"132":12.0,"133":12.0,"134":12.0,"135":13.0,"136":13.0,"137":13.0,"138":13.0,"139":13.0,"140":13.0,"141":13.0,"142":13.0,"143":13.0,"144":13.0,"145":13.0,"146":13.0,"147":13.0,"148":13.0,"149":13.0,"150":12.0,"151":12.0,"152":12.0,"153":12.0,"154":12.0,"155":12.0,"156":12.0,"157":16.0,"158":16.0,"159":16.0,"160":16.0,"161":12.0,"162":16.0,"163":16.0,"164":12.0,"165":16.0,"166":16.0,"167":16.0,"168":16.0,"169":16.0,"170":16.0,"171":12.0,"172":16.0,"173":16.0,"174":16.0,"175":16.0,"176":16.0,"177":16.0,"178":16.0,"179":16.0,"180":16.0,"181":16.0,"182":16.0,"183":16.0,"184":16.0,"185":16.0,"186":16.0,"187":16.0,"188":12.0,"189":12.0,"190":16.0,"191":16.0,"192":16.0,"193":16.0,"194":16.0,"195":16.0,"196":16.0,"197":16.0,"198":16.0,"199":16.0,"200":16.0,"201":16.0,"202":16.0,"203":16.0,"204":16.0,"205":16.0,"206":16.0,"207":16.0,"208":16.0,"209":16.0,"210":16.0,"211":16.0,"212":16.0,"213":12.0,"214":12.0,"215":12.0,"216":12.0,"217":12.0,"218":12.0,"219":12.0,"220":12.0,"221":12.0,"222":12.0,"223":12.0,"224":12.0,"225":12.0,"226":12.0,"227":12.0,"228":12.0,"229":12.0,"230":12.0,"231":12.0,"232":12.0,"233":12.0},"Sources__name":{"0":"","1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":"","9":"","10":"","11":"","12":"Clinical Trials Register Europe","13":"Clinical Trials Register Europe","14":"Clinical Trials Register Europe","15":"Clinical Trials Register Europe","16":"Clinical Trials Register Europe","17":"ClinicalTrials.gov","18":"ClinicalTrials.gov","19":"ClinicalTrials.gov","20":"ClinicalTrials.gov","21":"ClinicalTrials.gov","22":"ClinicalTrials.gov","23":"Novartis","24":"Novartis","25":"Novartis","26":"Novartis","27":"Novartis","28":"Novartis","29":"Novartis","30":"Novartis","31":"Novartis","32":"Novartis","33":"Novartis","34":"Novartis","35":"Novartis","36":"Novartis","37":"Novartis","38":"Novartis","39":"Novartis","40":"Novartis","41":"Novartis","42":"Novartis","43":"Novartis","44":"Novartis","45":"Novartis","46":"Novartis","47":"Novartis","48":"Novartis","49":"Novartis","50":"Novartis","51":"Novartis","52":"Novartis","53":"Novartis","54":"Novartis","55":"Novartis","56":"Novartis","57":"Novartis","58":"Novartis","59":"Novartis","60":"Novartis","61":"Novartis","62":"Novartis","63":"Novartis","64":"Novartis","65":"Novartis","66":"Novartis","67":"Novartis","68":"Novartis","69":"Novartis","70":"Novartis","71":"Novartis","72":"Novartis","73":"Novartis","74":"Novartis","75":"Novartis","76":"Novartis","77":"Novartis","78":"Novartis","79":"Novartis","80":"Novartis","81":"Novartis","82":"Novartis","83":"Novartis","84":"Novartis","85":"Novartis","86":"Novartis","87":"Clinical Trials Register Europe","88":"ClinicalTrials.gov","89":"ClinicalTrials.gov","90":"ClinicalTrials.gov","91":"ClinicalTrials.gov","92":"ClinicalTrials.gov","93":"ClinicalTrials.gov","94":"ClinicalTrials.gov","95":"ClinicalTrials.gov","96":"ClinicalTrials.gov","97":"ClinicalTrials.gov","98":"ClinicalTrials.gov","99":"ClinicalTrials.gov","100":"ClinicalTrials.gov","101":"ClinicalTrials.gov","102":"Clinical Trials Register Europe","103":"Clinical Trials Register Europe","104":"Clinical Trials Register Europe","105":"Clinical Trials Register Europe","106":"ClinicalTrials.gov","107":"ClinicalTrials.gov","108":"ClinicalTrials.gov","109":"ClinicalTrials.gov","110":"ClinicalTrials.gov","111":"ClinicalTrials.gov","112":"ClinicalTrials.gov","113":"ClinicalTrials.gov","114":"ClinicalTrials.gov","115":"ClinicalTrials.gov","116":"ClinicalTrials.gov","117":"ClinicalTrials.gov","118":"ClinicalTrials.gov","119":"Clinical Trials Register Europe","120":"ClinicalTrials.gov","121":"ClinicalTrials.gov","122":"ClinicalTrials.gov","123":"Clinical Trials Register Europe","124":"Clinical Trials Register Europe","125":"Clinical Trials Register Europe","126":"Clinical Trials Register Europe","127":"Clinical Trials Register Europe","128":"ClinicalTrials.gov","129":"ClinicalTrials.gov","130":"ClinicalTrials.gov","131":"ClinicalTrials.gov","132":"ClinicalTrials.gov","133":"ClinicalTrials.gov","134":"ClinicalTrials.gov","135":"Novartis","136":"Novartis","137":"Novartis","138":"Novartis","139":"Novartis","140":"Novartis","141":"Novartis","142":"Novartis","143":"Novartis","144":"Novartis","145":"Novartis","146":"Novartis","147":"Novartis","148":"Novartis","149":"Novartis","150":"ClinicalTrials.gov","151":"ClinicalTrials.gov","152":"ClinicalTrials.gov","153":"ClinicalTrials.gov","154":"ClinicalTrials.gov","155":"ClinicalTrials.gov","156":"ClinicalTrials.gov","157":"Clinical Trials Register Europe","158":"Clinical Trials Register Europe","159":"Clinical Trials Register Europe","160":"Clinical Trials Register Europe","161":"ClinicalTrials.gov","162":"Clinical Trials Register Europe","163":"Clinical Trials Register Europe","164":"ClinicalTrials.gov","165":"Clinical Trials Register Europe","166":"Clinical Trials Register Europe","167":"Clinical Trials Register Europe","168":"Clinical Trials Register Europe","169":"Clinical Trials Register Europe","170":"Clinical Trials Register Europe","171":"ClinicalTrials.gov","172":"Clinical Trials Register Europe","173":"Clinical Trials Register Europe","174":"Clinical Trials Register Europe","175":"Clinical Trials Register Europe","176":"Clinical Trials Register Europe","177":"Clinical Trials Register Europe","178":"Clinical Trials Register Europe","179":"Clinical Trials Register Europe","180":"Clinical Trials Register Europe","181":"Clinical Trials Register Europe","182":"Clinical Trials Register Europe","183":"Clinical Trials Register Europe","184":"Clinical Trials Register Europe","185":"Clinical Trials Register Europe","186":"Clinical Trials Register Europe","187":"Clinical Trials Register Europe","188":"ClinicalTrials.gov","189":"ClinicalTrials.gov","190":"Clinical Trials Register Europe","191":"Clinical Trials Register Europe","192":"Clinical Trials Register Europe","193":"Clinical Trials Register Europe","194":"Clinical Trials Register Europe","195":"Clinical Trials Register Europe","196":"Clinical Trials Register Europe","197":"Clinical Trials Register Europe","198":"Clinical Trials Register Europe","199":"Clinical Trials Register Europe","200":"Clinical Trials Register Europe","201":"Clinical Trials Register Europe","202":"Clinical Trials Register Europe","203":"Clinical Trials Register Europe","204":"Clinical Trials Register Europe","205":"Clinical Trials Register Europe","206":"Clinical Trials Register Europe","207":"Clinical Trials Register Europe","208":"Clinical Trials Register Europe","209":"Clinical Trials Register Europe","210":"Clinical Trials Register Europe","211":"Clinical Trials Register Europe","212":"Clinical Trials Register Europe","213":"ClinicalTrials.gov","214":"ClinicalTrials.gov","215":"ClinicalTrials.gov","216":"ClinicalTrials.gov","217":"ClinicalTrials.gov","218":"ClinicalTrials.gov","219":"ClinicalTrials.gov","220":"ClinicalTrials.gov","221":"ClinicalTrials.gov","222":"ClinicalTrials.gov","223":"ClinicalTrials.gov","224":"ClinicalTrials.gov","225":"ClinicalTrials.gov","226":"ClinicalTrials.gov","227":"ClinicalTrials.gov","228":"ClinicalTrials.gov","229":"ClinicalTrials.gov","230":"ClinicalTrials.gov","231":"ClinicalTrials.gov","232":"ClinicalTrials.gov","233":"ClinicalTrials.gov"},"Sources__link":{"0":"","1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":"","9":"","10":"","11":"","12":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","13":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","14":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","15":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","16":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","17":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","18":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","19":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","20":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","21":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","22":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","23":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","24":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","25":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","26":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","27":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","28":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","29":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","30":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","31":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","32":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","33":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","34":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","35":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","36":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","37":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","38":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","39":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","40":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","41":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","42":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","43":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","44":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","45":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","46":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","47":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","48":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","49":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","50":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","51":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","52":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","53":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","54":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","55":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","56":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","57":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","58":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","59":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","60":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","61":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","62":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","63":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","64":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","65":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","66":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","67":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","68":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","69":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","70":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","71":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","72":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","73":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","74":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","75":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","76":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","77":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","78":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","79":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","80":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","81":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","82":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","83":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","84":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","85":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","86":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","87":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","88":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","89":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","90":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","91":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","92":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","93":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","94":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","95":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","96":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","97":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","98":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","99":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","100":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","101":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","102":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","103":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","104":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","105":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","106":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","107":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","108":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","109":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","110":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","111":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","112":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","113":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","114":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","115":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","116":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","117":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","118":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","119":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","120":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","121":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","122":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","123":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","124":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","125":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","126":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","127":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","128":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","129":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","130":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","131":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","132":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","133":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","134":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","135":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","136":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","137":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","138":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","139":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","140":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","141":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","142":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","143":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","144":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","145":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","146":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","147":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","148":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","149":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","150":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","151":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","152":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","153":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","154":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","155":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","156":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","157":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","158":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","159":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","160":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","161":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","162":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","163":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","164":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","165":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","166":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","167":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","168":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","169":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","170":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","171":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","172":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","173":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","174":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","175":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","176":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","177":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","178":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","179":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","180":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","181":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","182":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","183":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","184":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","185":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","186":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","187":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","188":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","189":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","190":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","191":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","192":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","193":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","194":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","195":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","196":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","197":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","198":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","199":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","200":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","201":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","202":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","203":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","204":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","205":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","206":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","207":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","208":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","209":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","210":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","211":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","212":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","213":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","214":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","215":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","216":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","217":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","218":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","219":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","220":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","221":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","222":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","223":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","224":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","225":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","226":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","227":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","228":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","229":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","230":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","231":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","232":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","233":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000"}}